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Chapter 1  
 
General introduction 
 
Alessandro Tocchio1,2 
1Fondazione Filarete, Viale Ortles 22/4, 20139 Milano, Italy; 2SEMM, European School of Molecular 
Medicine, Campus IFOM-IEO, Via Adamello 16, 20139 Milano. 
 
Background   
The emerging field of tissue engineering is dedicated to restore, maintain 
or improve the functions of damaged or lost human tissues [1]. Current 
tissue engineering approaches include: i) the use of cells isolated from 
the patient and then injected in a desired location of the body, ii) the use 
of injected or implanted biomaterials and iii) their combination to create 
in vitro functional tissues to be used as transplants or in vitro test 
systems [2, 3]. In the latter, cells are firstly isolated from the patient and 
subsequently expanded in-vitro. When the sufficient amount of cells is 
reached, they are seeded and cultured on a biomimetic scaffold in a 
controlled culture environment. Once the construct become mature, it is 
implanted in the desired site of the patient’s body to complete the tissue 
regeneration [4]. In this method the scaffold acts as a support for tissue 
growth and maturation both in vitro and when implanted in vivo, degrading 
as cells deposit their extracellular matrix [5]. However, despite significant 
successes have been achieved with this approach over the last 20 years, 
a number of challenges still remain, preventing a pervasive clinical 
application of tissue engineering [6,7]. Among all the scientific issues, 
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one of the main challenges is the development of biomaterials able both 
to support and guide cell growth, providing the appropriate biochemical 
and mechanical stimuli for the specific engineered tissue [8,9]. Another 
key issue lays in the design of biomaterials with a complex three-
dimensional architecture [5] able to match the requirements of 
hierarchical porosity and roughness, and which mimic the complexity of 
the in vivo milieu. A particular aspect of this problem is to overcome the 
mass transport limit by enabling the provision of sufficient nutrients to 
the engineered tissue, during in vitro growth, and enhancing the formation 
of blood vessels, after implantation [10]. In fact, any tissue that is more 
than a few 100 microns thick needs a vascular system because every cell 
requires to be close enough to capillaries to absorb the oxygen and vital 
nutrients that diffuse constantly out of these tiny vessels [7]. When this 
condition is not satisfied, cells quickly become irreparably damaged. 
Nowadays, only skin, cartilage and bladder grafts are successfully used in 
clinics [10–16] while cornea grafts are far ahead [17,18]. This is mainly 
thanks to their lower requirement for nutrients and oxygen that can be 
met by the host's vascularization. However, only few tissues can be 
successfully supplied via diffusion from distant blood vessel systems 
[19,20]. Indeed, this approach fails when applied to large and complex 
tissues [4]. This is due to the fact that the formation of new blood 
vessels is a slow phenomenon and the deficiency of nutrients supply 
rapidly causes widespread cell death in graft cores [21]. At present, 
diffusion limitation is reducing the size of the engineered tissues to 
smaller than clinically relevant dimensions. For this reason, overcoming 
the current inability to engineer tissue with controlled blood vessel 
systems architecture, mimicking the branched vascular system of the 
human body [22], is critical to create large and complex in vitro tissues 
[23] and to transfer tissue engineered constructs to the clinic [4,24,25].  
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Aim of study 
In the light of this overview, it is evident that the main scientific challenge 
in tissue engineering lays in satisfying cellular demands both in terms of 
scaffolding materials, providing adequate biochemical and mechanical 
stimuli, and also in terms of three-dimensional architecture, mimicking 
the complex organization of natural cellular microenvironment. The aim of 
this PhD work, merging the study of novel biomaterials and the 
development of original micro and nanofabrication methods, is to create 
enabling technologies towards the design of innovative scaffolds for thick 
and complex tissues engineering.  
 
Outline 
In this work, customizable biocompatible hydrogels were combined with 
innovative fabrication approaches to engineer scaffolds with controlled 
chemical, mechanical and biological features and a hierarchical three-
dimensional architecture. The abilities of these scaffolds to supply 
nutrient perfusion and mass transport, and to promote in vitro 
vascularization in large constructs are evaluated and discussed in detail.  
In Chapter 2 the design of novel RGD-mimetic poly(amidoamine) (PAA) 
based hydrogels with wide and controlled degradation rate and improved 
mechanical and biological properties for biomedical applications is 
presented. The results presented in this study indicate that PAA 
hydrogels are excellent biomaterials for the fabrication of tissue 
engineering scaffolds. 
In Chapter 3 PAA hydrogels were further investigated to design a novel 
photopolymerizable matrix for three-dimensional cell encapsulation and 
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microfluidic applications. The results support the use of PAA hydrogels as 
tunable and inexpensive biomaterials for the creation of complex cell-
laden microengineered constructs. 
In Chapter 4 PAA hydrogels were fabricated in to macro porous foams 
with the aim to recreate the complex microarchitecture of natural 
extracellular matrix. An extensive screening of the biological, chemical 
and mechanical properties was performed. The results confirmed that 
macroporous PAAs hydrogels are able to support and enhance three-
dimensional cell growth and can be considered an optimal scaffold for 
soft tissue engineering. 
In Chapter 5 the development of innovative fabrication approaches to 
engineer scaffolds with a perfusable microfluidic network is presented 
[28]. Branched microfluidic networks were embedded within hydrogel 
matrices through an innovative method based on sacrificial templates. 
Results demonstrated that perfused microfluidic networks are able to 
sustain the cell viability of murine fibroblast in the core of PAA hydrogel 
cell-laden constructs and, when seeded with endothelial cells, to form 
branched endothelialized networks.  
In Chapter 6, there is a general review of the results obtained in this 
work. 
The Appendix explores issues involved in technological transfer of 
nanomedicine products [29]. A detailed analysis of market, competitors 
and investors in the sector has been performed. This overview aims to 
help scientists, startup mangers and investors to understand the key 
dynamics and successful cases in the transfer of nanotechnology in 
medicine.  
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Poly(amidoamine)-based hydrogels with tailored 
mechanical properties and degradation rates for 
tissue engineering 
 
Alessandro Tocchioa,b,1, Federico Martelloa,1 et al. 
aFondazione Filarete, Viale Ortles 22/4, 20139 Milano, Italy; bSEMM, European School of Molecular 
Medicine, Campus IFOM-IEO, Via Adamello 16, 20139 Milano, Italy; 1These authors contributed 
equally to this work. 
 
This chapter has been published: Martello F, Tocchio A, Tamplenizza M, Gerges M, Pistis 
V, Recenti V, Bortolin M, Del Fabbro M, Argentiere S, Milani P, Lenardi C. 
Poly(amidoamine)-based Hydrogels with Tailored Mechanical Properties and Degradation 
Rates for Tissue Engineering. Acta Biomaterialia 2014;10(3):1206–1215 
 
1. Introduction 
Hydrogels are defined as three-dimensional networks of hydrophilic 
polymers that are able to absorb up to hundreds of times its dry weight in 
water, thus acquiring biomechanical properties similar to the extracellular 
matrix (ECM) and allowing cells to adhere, proliferate and differentiate 
onto their surface. Several classes of hydrogels are characterized by 
excellent biocompatibility, minimal inflammatory reaction and tissue 
damage, which make them attractive materials for tissue engineering and 
regenerative medicine [1]. Hydrogels based on synthetic polymers, thanks 
to their versatility and low costs compared with natural biomaterials, have 
been successfully employed in a variety of biomedical applications, 
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ranging from ophthalmic and vascular prostheses to drug delivery and 
soft-tissue replacement [2-4]. In particular, hydrogels based on poly(2-
hydroxyethylmethacrylate) (PHEMA) have shown to hold several 
advantages over other synthetic polymers [5]. Indeed, they display 
excellent biocompatibility in vivo and can be fabricated with different 
architectures and mechanical properties similar to natural tissue [6-9]. 
Even though PHEMA homopolymers cannot be degraded enzymatically or 
by acidic/alkaline solutions, copolymers containing HEMA were found to 
be biodegradable [8]. Another promising class of synthetic polymers for 
tissue engineering application are poly(amido-amine)s (PAAs) [10]. They 
are obtained by Michael-type addition of bis-acrylamides to primary 
amines and/or secondary diamines, under mild conditions. Different 
bioactive molecules can be incorporated in the PAA's backbone by 
covalent attachment during the synthetic process [11-13]. PAA-based 
hydrogels show good biocompatibility and are extremely versatile, being 
easily modifiable by introducing different comonomers that carry 
additional chemical functions such as carboxylic acids, thiols and amino 
groups [14-20]. Biological properties of synthetic materials can be further 
improved through surface/bulk modification with bioactive functional 
groups able to interact specifically with cell receptors [21,22]. For 
example, cell adhesion has been improved by introducing the tripeptide 
arginin-glycin-aspartic acid (RGD). The RGD motif is a structural element 
of many adhesion proteins, such as fibronectin, laminin, and vitronectin, 
which is specifically recognized by cell surface receptors, like integrins 
[23,24]. However, despite their good biological properties and low 
immunological reaction risk, RGD-modified hydrogels require complex 
synthetic procedure and high production costs [25]. To overcome these 
hurdles, Tanahashi and coworkers modified the surface of poly(propylene 
fumarate-co-ethylene glycol) hydrogels with 4-aminobutylguanidine (ABG) 
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units. Interestingly, he demonstrated that the increased fibroblast cell 
adhesion was related to the RGD-mimetic structure of the guanidine side 
groups [26]. The introduction of ABG units in a cross-linked amphoteric 
PAA hydrogel, as demonstrated by Ferruti and co-workers, resulted in an 
increased fibroblast cell adhesion [15]. However, PAA hydrogels displayed 
some drawbacks such as non controllable degradation rate, scarce 
mechanical properties and high risk of ruptures during hydrogel washing 
due to osmotic pressure [14-15, 27]. Since it has been demonstrated 
that the ABG residue in PAA hydrogels maintains cell adhesion promoting 
ability even when copolymerized with other monomers, we supposed that, 
by introducing HEMA as acrylic comonomer in the three-dimensional 
network, it would be possible to control degradation rate and enhance 
mechanical properties without hampering the cell adhesion efficiency 
[28]. Therefore, in order to develop reliable and effective supports for 
tissue engineering, we tested a library of PAA-based hydrogels, obtained 
by varying several synthetic parameters such as monomer ratio and 
reaction time (Fig. 1A and 1B). With the aim to improve mechanical 
properties and to control the degradation rate of PAAs hydrogels, PHEMA 
was grafted to PAA chains by free-radical polymerization. The obtained 
PAA-based hydrogels showed finely controllable degradation rate, high 
compressive strength, allowed a fast washing process and promoted cell 
adhesion and proliferation with MDCK cells. 
 
2. Materials and Methods 
2.1 Materials 
4-aminobutylguanidine sulfate (ABG), ammonium persulfate (APS), 2-
hydroxyethylmethacrylate (HEMA), 2-hydroxy-4-(2-hydroxyethoxy)-2-
methylpropiophenone (HMP), lithium hydroxide monohydrate (LiOH), 
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hydrochloric acid (HCl), N,N-ethylendiamine (EDA), trichlorododecylsilane 
(TCS), and tetramethylethylenediamine (TEMED), potassium chloride 
(KCl), sodium chloride (NaCl), sodium phosphate dibasic (Na2HPO4), 
potassium phosphate monobasic (KH2PO4) were purchased from Sigma-
Aldrich at the highest degree of purity available and used as received. 
Milli-Q grade water was used in all the experiments. The PBS buffer used 
in the experiments contained 2.69 mM KCl, 136.89 mM NaCl, 3.21 mM 
Na2HPO4, 1.47 mM KH2PO4. All solvents were purchased from Sigma 
Aldrich and used without further purifications. Finally, 2,2-
bis(acrylamido)acetic acid (BAC) was prepared as previously reported and 
its purity (99.9%) determined both by acid-base titration and by NMR 
spectroscopy [29]. The reference PAA hydrogel was prepared according to 
literature (see “Preparation procedure for AGMA1-75 hydrogel”) [17]. 
 
2.2 Glass slide silanization and mold fabrication 
Glass slides were silanized for fabricating cylindrical molds. Briefly, glass 
slides were washed with acetone, activated by plasma oxygen (70 W, 70 
s) and immersed in a TCS solution (5% v/v in petroleum ether) for 10 
minutes. Afterwards, glass slides were washed in succession with 
petroleum ether and ethanol, dried with gentle air flow and stored at room 
temperature (RT). Two types of mold were then prepared by interposing 
between two silanized glass slides a preformed silicone spacer of 0.3 or 
1 mm thickness and 5 or 20 mm of internal diameter, respectively. 
 
2.3 Synthesis of PAA (PAA-based hydrogels) and PAH (PAA-HEMA-based 
hydrogels) series 
In a 50 mL round-bottom flask, BAC (1 eq), water, lithium hydroxide (1.2 
eq) and ABG (specific amounts are reported in Table 1) are added in this 
order so as to obtain a BAC concentration of 3 mM. After 24 hours 
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stirring, 0.12 meq of APS (aqueous solution, 0.11 mM) was added in 
presence or absence of HEMA, to achieve PAH and PAA series, 
respectively. The resulting mixture was injected into the cylindrical mold, 
and allowed to react at RT for 24 hours. Then the hydrogels were 
recovered from the mold and washed (see "Hydrogel washing procedure" 
paragraph). 
 
2.4 Synthesis of OPAA (PAA Oligomers-based hydrogels) and OPAH (PAA 
Oligomers-HEMA-based hydrogels) series 
The mixture consisting of BAC, LiOH and ABG was prepared with the 
same procedure followed for PAA and PAH series (specific amounts are 
reported in Table 2), stirred for 72 h at RT, then diluted 1:50 with bi-
distilled water and neutralized with 1.0 M hydrochloric acid. 
Subsequently, the solution was purified from unreacted BAC by 
ultrafiltration using a 1000 Da cut-off membrane until no sodium chloride 
was present in the eluates and subsequently freeze-dried (Telstar Cryodos 
50). The purified PAA oligomers (yield, 70%) were dissolved in PBS buffer 
to obtain a 42% w/w oligomer concentration. The photoinitiator HMP 
(50% w/v in DMSO) was added to the oligomers solution to a final 
concentration of 0.5% (w/w) with or without HEMA, to achieve OPAH and 
OPAA series, respectively. The reacting mixture was stirred for 1 minute, 
injected in the glass mold and photopolymerized by exposure to long-
wavelength UV light (365 nm, 10 mW/cm2) for 7 min.  Then the hydrogels 
were recovered from the mold and treated with the same procedure 
followed for PAA and PAH series. The oligomers' average molecular 
weight is shown in Table 2. 
PAA-based hydrogels with tailored mech. properties and degr. rates for tissue eng. 
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Table 1. Monomer molar amount, reaction specifications and swelling data related to PAA 
and PAH hydrogel series. aStarting reagent molar amounts related to 1 mmol of BAC. 
bReaction time of the Michael-type addition reaction. 
ABGa HEMAa Reaction Swelling
[mmol] [mmol] timeb ratio (%)
PAA 3a 0.25 - 3h 150%
PAA 3b 0.5 - 3h 170%
PAA 3c 0.9 - 3h 195%
PAA 24a 0.25 - 24h 210%
PAA 24b 0.5 - 24h 250%
PAA 24c 0.9 - 24h 263%
PAA 72a 0.25 - 72h 290%
PAA 72b 0.5 - 72h 340%
PAA 72c 0.9 - 72h 351%
PAH l3a 0.25 0.125 3h 148%
PAH l3b 0.5 0.15 3h 214%
PAH l3c 0.9 0.19 3h 227%
PAH l24a 0.25 0.125 24h 176%
PAH l24b 0.5 0.15 24h 256%
PAH l24c 0.9 0.19 24h 233%
PAH l72a 0.25 0.125 72h 190%
PAH l72b 0.5 0.15 72h 281%
PAH l72c 0.9 0.19 72h 257%
PAH m3a 0.25 0.313 3h 141%
PAH m3b 0.5 0.375 3h 155%
PAH m3c 0.9 0.475 3h 168%
PAH m24a 0.25 0.313 24h 164%
PAH m24b 0.5 0.375 24h 175%
PAH m24c 0.9 0.475 24h 179%
PAH m72a 0.25 0.313 72h 175%
PAH m72b 0.5 0.375 72h 182%
PAH m72c 0.9 0.475 72h 186%
PAH h3a 0.25 0.625 3h 124%
PAH h3b 0.5 0.75 3h 131%
PAH h3c 0.9 0.949 3h 143%
PAH h24a 0.25 0.625 24h 136%
PAH h24b 0.5 0.75 24h 146%
PAH h24c 0.9 0.949 24h 143%
PAH h72a 0.25 0.625 72h 149%
PAH h72b 0.5 0.75 72h 146%
PAH h72c 0.9 0.949 72h 166%
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Table 2. Monomer molar amounts, reaction specifications, GPC and swelling data of OPAA 
and OPAH series. aStarting reagent molar amounts related to 1 mmol of BAC. bPurification 
has been carried out by ultrafiltration on 1000 Da cut-off membrane and subsequent 
freeze-drying. 
 
2.5 Washing procedure of hydrogel slabs 
In order to remove unreacted monomers and other impurities, hydrogel 
slabs were immersed in a water/ethanol solution under gentle stirring on 
an orbital shaker. The volume ratio of hydrogel to washing solution was 
1:100. The washing solutions were different as a function of the hydrogel 
slabs to be purified. Reference PAA hydrogel: washing solutions were 
replaced after at least 3 hours using in sequence the following solutions: 
water/ethanol 6/4, 4/6, 3/7, 2/8, 1/9, ethanol 99% (twice), 
ABGa HEMAa Oligomerb Swelling at
[mmol] [mmol] Mw/Mn 72h (%)
OPAA 1 0.515 - 1100/1000 235%
OPAA 2 0.724 - 2100/1900 290%
OPAA 4 0.852 - 4300/4100 363%
OPAA 8 0.923 - 8700/8200 416%
OPAH l1 0.515 0.242 1100/1000 219%
OPAH l2 0.724 0.276 2100/1900 275%
OPAH l4 0.852 0.296 4300/4100 338%
OPAH l8 0.923 0.308 8700/8200 378%
OPAH m2 0.724 0.552 1100/1000 240%
OPAH m4 0.852 0.593 4300/4100 325%
OPAH m8 0.923 0.615 8700/8200 343%
OPAH h2 0.724 0.845 1100/1000 205%
OPAH h4 0.852 0.907 4300/4100 279%
OPAH h8 0.923 0.942 8700/8200 330%
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water/ethanol 1/9, 2/8, 3/7, 4/6, 6/4, 7/3, 8/2, 9/1, bidistilled water 
(4 times). PAA series; washing solutions were replaced after at least 60 
minutes using the same sequence of solutions indicated for the 
reference PAA hydrogel. PAH, OPAA and OPAH series; washing solutions 
were replaced after at least 60 minutes in the following order: 
water/ethanol 50/50, 25/75, ethanol 99% (twice), water/ethanol 25/75, 
50/50, 75/25, bidistilled water (4 times). The wastewater resulting from 
the washing process was freeze-dried and the impurities recovered were 
analyzed by 1H-NMR until no impurities were detected. The 
characterization of purified hydrogel slabs was performed within 24 hours 
after the last washing cycle. 
 
2.6 Chemical characterization 
Size exclusion chromatography (SEC) traces of PAA-based polymers were 
obtained with Toso-Haas 486 columns using 0.1 M Tris buffer pH 
8.00±0.05 as a mobile phase, with a UV detector operating at 230 nm. 
Sample concentration: 10 mg/ml; flow rate: 1 ml/min. The molecular 
weight determination was based on pullulan standards. Proton nuclear 
magnetic resonance (1H-NMR) spectra were run on a Bruker Advance 400 
spectrometer operating at 400.132 MHz. Sample concentration: 30 mg 
of oligomer per mL of deuterium oxide (Sigma-Aldrich). 1H-NMR spectra 
are given in the Supporting Information section. Fourier-transform infrared 
spectroscopy (FTIR) spectra of dry hydrogel samples were measured 
using a Jasco FTIR 300 spectrophotometer. Sample preparation: 
hydrogels disks of 0.3 mm height and 5 mm diameter were dried for 5 
days under vacuum (10 mBar) and subsequently analyzed through an 
ATR-FTIR accessory with a Zn-Se crystal. 
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2.7 Mechanical characterization 
The compressive strength was measured by using a testing machine 
equipped with a 100 N load cell (BR EMT503 A, MP Strumenti, Italy). The 
hydrogels were prepared by injection molding into 15 mm diameter, 15 
mm height cylinders. Axial load was applied with a crosshead constant 
speed of 1 mm min-1 up to rupture. Six specimens of each sample were 
tested at 20 °C and 60% relative humidity. 
 
2.8 Equilibrium swelling measurements 
Hydrogels cylindrical slabs, having 0.5 cm diameter and 0.3 mm 
thickness, were previously dried at 20 °C and 0.1 Torr. Their weight was 
40 mg ± 2 mg. Each specimen was placed inside a 10 mL tube 
containing 5 mL PBS (pH 7.0), incubated at 37 °C and weighed at regular 
intervals. The uptake of water was measured gravimetrically until the 
maximum mass was obtained. The percent amount of water absorbed 
was calculated using the following formula: 
Swelling (%) = Wt / Wd × 100, (1) 
where Wt is the hydrogel sample’s weight at time t and Wd is the weight of 
the dry sample at time zero. 
 
2.9 Degradation study 
Hydrogels cylindrical slabs having 0.5 cm diameter and 0.3 mm 
thickness, were placed inside a 10 mL test tube containing 5 mL PBS (pH 
7.0) and incubated at 37 °C. At fixed time points they were freeze-dried 
and weighed. The percent degradation was calculated using the following: 
Degradation (%) = Wf / Wd × 100, (2) 
where Wf is the dry weight at time t, Wd is described before. 
PAA-based hydrogels with tailored mech. properties and degr. rates for tissue eng. 
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2.10 Cell Culture 
Madin-Darby Canine Kidney (MDCK) epithelial cells (NBL-2; ATCC) were 
maintained in Minimum Essential Medium with Earle’s balanced Salts 
(MEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine, 100 units ml-1 penicillin, 100 µg ml-1 streptomycin, 1 mM 
pyruvic acid (sodium salt) in 5% CO2, 98% air-humidified incubator 
(Galaxy S, RS Biotech) at 37°C. Subcultures were routinely established 
every 48-72 h day. 
 
2.11 2-D cell culture on hydrogel disks 
MDCK (1.25 x 104 cells cm-2) cells were seeded into 12 well plates 
containing UV-sterilized hydrogel discs (2 cm diameter and 1 mm 
thickness) containing dishes (12-24 wells) and were cultured for 24-48h 
monitoring their growth with an inverted microscope (Axiovert 40 CFL; 
Zeiss, Germany). Digital images were collected with an AxioCam ICm1. 
 
2.12 Cell attachment/spreading assay 
After 24 h, cells on discs were washed with PBS, fixed with 3% 
paraformaldehyde (15 minutes, RT), washed again and stained with 
BisBenzimide H 33258 (Hoechst) 5 µg/ml. Then, fluorescent nuclei 
digital images were collected (8 fields for disc, 10X) and their number 
was measured by ImageJ software. 
 
2.13 Immunofluorescence staining 
 Experiments were performed after 48 hours from cell plating. Samples 
were fixed and immunostained for F-actin (the actin polymer form), 
vinculin (a membrane-cytoskeletal protein in focal adhesion plaques) and 
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nucleus. For cell staining we used the following: Monoclonal Anti-Vinculin 
primary antibody (clone hVIN-1), Alexa Fluor® 488 goat anti-mouse 
IgG1(γ1) secondary antibody (Invitrogen), Alexa Fluor® 555 phalloidin 
(Invitrogen) and nuclei were counterstained with DAPI (4’-6-Diamidino-2-
phenylindole). Briefly, at room temperature cells were rinsed twice with 
PBS and fixed with 4% paraformaldehyde in PBS for 15 min; after 
washing, cells were treated with a permeabilization buffer containing 
0.2% BSA (Albumin from Bovine Serum, Fraction V, Biochemical) and 
0.1% Triton X-100 for 10 min, blocked with 2% BSA, stained with anti-
vinculin, washed with 2% BSA, stained with Alex488-anti-mouse 
secondary antibody and Alexa555-phalloidin in 2% BSA for 45 min, 
washed twice in PBS and stained with DAPI. Samples were rinsed twice 
with PBS and mounted with Mowiol 4-88 (Calbiochem). 
 
2.14 Cytotoxicity assay 
MDCK (1.25 x 104 cells cm-2) cells were seeded into dishes adding PBS 
recovered from hydrogels degradation test after 16 weeks and incubated 
at 37°C in 5% CO2 and 98% air-humidified for 48 h. Then a MTT 
colorimetric assay (Roche) for measuring enzymes activity was performed 
(see company data sheet for details). Formazane product absorbance 
(550 nm) was measured (Tecan sunrise). 
 
2.15 Statistical Analysis  
Each hydrogel type was tested at least 5 times with similar results. All 
data are expressed as 100*sample arithmetic mean/control arithmetic 
mean ± S.E.M.. Significance of differences was determined using 
Student’s t-test (p<0.05). 
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3. Results 
 
3.1 Hydrogel synthesis 
In this work, four different series of amphoteric PAA hydrogels containing 
ABG as RGD-mimetic unit were prepared by a two-step synthesis. At first, 
a Michael-type addition was carried out in presence of ABG and an 
excess of BAC, to achieve diacrylamide-terminated homobifunctional PAA 
oligomers [30]. In the second step, the reaction mixture containing the 
PAA oligomers and unreacted BAC was polymerized by free-radical 
polymerization in presence or absence of HEMA, to obtain PAH (PAA-
HEMA-based hydrogels) and PAA (PAA based hydrogels) series, 
respectively. Alternatively, PAA oligomers were purified from unreacted 
BAC by ultrafiltration, and then UV-induced photopolymerization was run 
either with or without HEMA, thus obtaining OPAH (PAA Oligomers-HEMA-
based hydrogels) and OPAA (PAA Oligomers-based hydrogels) series (Fig. 
1A).  
The ratio of acrylic to PAA chains ratio was correlated to water uptake, 
degradation rate in physiological conditions, compressive strength and 
biological response with MDCK cells. Moreover, to assess the role of 
acrylic chains in the above-mentioned physico-chemical and biological 
properties of the synthesized hydrogels, a PAA hydrogel without acrylic 
chains was prepared according to the literature method and used as 
reference [17]. 
In order to study the effect of the PAA chains length in the hydrogel, 
diacrylamide-terminated homobifunctional PAA oligomers of controlled 
molecular weight ranging from 1000 to 8000 Da were synthesized by 
varying the amount of BAC added into the reaction mixture. The chemical 
structure of the synthesized oligomers was verified by 1H-NMR 
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spectroscopy and FT-IR. The data related to monomers ratios, reaction 
time, GPC data and the equilibrium swelling of the PAA-based hydrogels 
obtained in the presence or absence of unreacted BAC are shown in 
Table 1 and 2, respectively. 
In all preparations, the relative amounts of the monomers were adjusted 
in order to balance the total numbers of aminic hydrogens and the 
acrylamido functions. The main factors affecting the average molecular 
weight of the final oligomers are the reaction time and the ratio of the 
total numbers of aminic hydrogens with the acrylamido functions. The 
average molecular weight of the starting PAA oligomers is inversely 
proportional to the hydrogel's cross-linking degree [10]. 
The hydrogels' optical transparency was qualitatively evaluated to assess 
their suitability for in vitro experiments. The transparency was found 
higher by increasing the reaction time of the Michael-type addition step, 
the ABG/BAC ratio and the concentration of HEMA (Fig. 2). FT-IR analyses 
of dry hydrogels confirmed that the polymer composition was consistent 
with their ratio in the starting reagent mixture (data not shown). 
A critical point in hydrogel preparation is the purification from unreacted 
monomers or other impurities. Usually, this step requires large amounts 
of water and time-consuming procedures, which can take more than 10 
days. However, such an extensive extractions can cause hydrogels 
ruptures due to internal mechanical stress caused by swelling. In this 
study, the hydrogels synthesized showed an improved resistance to 
osmotic shock, allowing a fast washing process ranging from 2 (PAH, 
OPAA and OPAH series) to 3 working days (PAA series). 
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Figure 1. (a) Synthetic scheme of PAA, OPAA, PAH and OPAH hydrogel series [30]; (b) 
chemical structure of the synthesized hydrogels. 
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Figure 2. Comparison of the optical transparency of selected hydrogels as a function of 
the following parameters, increasing from left to right: (a) Michael-type addition reaction 
time, (PAA 3a, PAA 24a and PAA72a); (b) ABG/BAC molar ratio, (PAA 72a, PAA 72b and 
PAA 72c); (c) concentration of HEMA, (OPAA 2, OPAH l2 and OPAH h2). 
 
3.2 Hydrogel characterization 
The equilibrium swelling ratio was systematically examined as a function 
of the starting reagents composition (Table 1 and 2). As expected, the 
PAA and PAH hydrogels displayed a lower swelling ratio compared to 
OPAA and OPAH because of the higher degree of cross-linking. Further, 
the presence of HEMA generally decreased the swelling ratio, which could 
be due to the lower hydrophilicity of PHEMA compared to PAA chain. In 
confirmation of this, it was noted that PAH and OPAH series showed 
higher swelling ratio in ethanol, compared to PAA and OPAA series [31].  
A major hurdle in the development of PAA hydrogels for tissue engineering 
is their brittleness when external forces are applied, especially during 
washing and handling steps [15,32]. The hydrogels synthesized in this 
study showed improved compressive strength, thanks to the presence of 
cross-linked acrylic chains within the three dimensional PAA polymeric 
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network. To assess the mechanical properties of the synthesized 
hydrogels compressive strength measurements were performed on 
selected samples representing the four developed hydrogels series and 
the reference PAA hydrogel lacking acrylic chains. As shown in Fig. 3, the 
compressive strength was clearly enhanced in all the PAA-based 
hydrogels compared to reference PAA hydrogel. The difference between 
PAA/PAH series and the OPAA/OPAH series is due to the different cross-
linking density, since in the latter case the excess of unreacted 
bisacrylamide was removed by ultrafiltration, thus decreasing the number 
of bifunctional monomers in the reacting mixture and thus the degree of 
cross-linking. The inclusion of HEMA does not affect the rupture strain, 
whereas plays a key role in the compression strength, being negative for 
the PAH and positive for OPAH hydrogels. This is likely due to the fact 
that the mechanical behavior of the HEMA containing PAA hydrogels tend 
to approach those of pure PHEMA hydrogels [33]. 
 
Figure 3. Representative stress-strain curves of PAA 24a (a), PAH h24a (b), reference PAA 
hydrogel (c), OPAH h2 (d) and OPAA 2 (e). In the inset table, mean values of stress and 
strain at rupture point are presented ± standard deviation on six samples. 
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3.3 Degradation rate 
The degradation rate was found to increase with the starting PAA 
oligomers' average molecular weight as expected due to PAAs’ 
degradation mechanism involving hydrolytic cleavage of the amidic bond 
[10]. Moreover, the time required for a complete degradation was higher 
if compared to the reference PAA hydrogel lacking acrylic chains [15]. The 
PAA and PAH hydrogels displayed a lower degradation rate compared with 
OPAA and OPAH hydrogels (Fig. 4) because of their higher crosslinking 
density and the fact that the amides of the Michael-type adduct are more 
easily hydrolysable than those of the bisacrylamide itself. Interestingly, 
the degradation rate of OPAA and OPAH was high at the beginning (25-
37% of the hydrogel dry weight lost in the first 20 days) and moderate in 
the following weeks, resulting in the range of 49-82% after six months. 
 
Figure 4. Degradation behavior over time of selected synthesized hydrogels representing 
PAA, PAH, OPAA and OPAH series (lines are added for clarity). Experimental data are 
presented as mean ± standard deviation. 
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On the contrary, the PAA and PAH showed a slower and more linear 
degradation rate, leading to loss of dry weight in the range 5% - 50% after 
six months. The presence of HEMA monomer units in the PAA polymeric 
network reduced the hydrogel degradation rate, which is consistent with 
the lower swelling degree of PAH/OPAH towards PAA/OPAA. Indeed the 
lower was the quantity of water absorbed by the macromolecular network 
the lower the degradation rate. 
 
3.4 Biological behavior 
To assess the adhesion and proliferation efficiency of the PAA-based 
hydrogels, Madin-Darby Canine Kidney (MDCK) cells were chosen as a 
model epithelial cell line. The hydrogels were seeded at a cell density of 
10,000 cells cm-2 and observed for 96 hours, when generally confluence 
was reached. As shown in Fig. 5 and 6, all the tested hydrogels were 
shown to promote cell adhesion. Moreover, no toxic substances were 
released in the environment during cell culture, as a high number of 
viable cells was found adherent to the Tissue Culture Polystyrene (TCPS) 
well bottom. After 2 hours, cells on both the hydrogels and control glass 
appear to be mainly round and pearly. After 4 hours a substantial amount 
of cells on samples PAA 24b, PAH m24a, OPAA 1, OPAH l2 and control 
glass started to show a polygonal-like morphology typical of the 
phenotype of adherent MDCK cells. On the same hydrogels, at 24 and 48 
hours after seeding, cells start to form a monolayer, which was already 
complete, whereas on the control glass it needed 72 hours to reach 
confluence. On all the remaining hydrogels confluence was reached after 
72 to 96 hours. MDCK cells grown on the reference PAA hydrogel without 
acrylic chain exhibited modest adhesion and a proliferation comparable 
with the glass control (data not shown). 
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Figure 5. Cell proliferation at 48h after cell seeding of the PAA and PAH hydrogels series 
compared with glass control. In the table on the left side, "H" is the molar percentage of 
HEMA over the sum of BAC and ABG in the polymerizing mixture; "t" is referred to the 
reaction time of the Michael-type addition step; "r" is the ABG/BAC molar ratio. Horizontal 
bars are referred to the corresponding hydrogel in the table and represent the proliferation 
efficiency. The symbol “” represents statistical significance by students T-test (p<0.05), 
comparing each sample against control. Optical images of the hydrogels with the highest 
proliferation at 48h are shown on the right side (scale bar, 150 µm). 
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Interestingly, the introduction of HEMA moieties seemed not to hamper 
the adhesion properties of PAA hydrogels. In particular, PAH hydrogels 
with r = 0.25 showed higher cell adhesion and proliferation compared to 
the sample with r = 0.5 and 0.9 for all the reaction time tested. Among 
all the tested hydrogels, PAA 24b displayed the highest proliferation; the 
hydrogels obtained after 48 and 72 h reaction time appear to perform 
generally better than those synthesized after 24 h reaction time. This 
could be related to the surface chemistry, whose changes depend on 
starting monomer ratio and the Michael-type addition reaction time [10]. 
 
 
Figure 6. Cell proliferation efficiency at 48h after cell seeding of the OPAA and OPAH 
hydrogels series compared with glass control. In the table on the left side, "H" is the 
molar percentage of HEMA over the sum of BAC and ABG in the polymerizing mixture; "r" 
is the ABG/BAC molar ratio. Horizontal bars are referred to the corresponding hydrogel in 
the table and represent the proliferation efficiency as measured by MTT assay. The 
symbol “” represents statistical significance by students T-test (p<0.05), comparing 
each sample against control. Optical images of the hydrogels with the highest proliferation 
at 48h are shown on the right side (scale bar, 150 µm). 
 
On average, the OPAA and OPAH hydrogels showed a higher proliferation 
than the PAA and PAH hydrogels. The inclusion of HEMA chains into the 
OPAH hydrogels slightly improved the cellular adhesion and proliferation, 
with the exception of OPAH l1, showing lower proliferation than OPAA 1, 
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probably due to unfavorable effects of stiffness and surface chemistry 
(Fig. 6). The results obtained for OPAA and OPAH showed that the lower 
the starting oligomer's molecular weight, the higher was the cell 
proliferation. However, the cellular morphology seems to be somewhat 
rounded (Fig. 7). Finally, the cytotoxicity of the degradation products was 
measured by MTT assay. The MDCK cells were mixed with solutions 
retrieved from degradation tests after 16 weeks, and no evident toxicity 
of the degradation products was observed. 
 
 
Figure 7. Adhesion complexes and actin organization of adherent MDCK cells after 48h 
from seeding on glass (a), PAA 24b (b), PAH l24a (c), OPAA 1 (d) OPAH l2 (e). Vinculin 
(green), actin (red) and nucleus (blue) fluorescent staining (scale bar, 50 µm). 
 
4. Discussion 
Here, a thorough investigation on the mechanical and biological 
properties of PAA-based hydrogel has been performed to design tailorable 
scaffolds for tissue engineering. Four different series of hydrogels were 
synthesized by varying the following parameters: reaction time of the 
Michael-type addition, ABG/BAC molar ratio and, only for PAH and OPAH 
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series, HEMA/(BAC+ABG) molar ratio. We investigated the effect of these 
experimental parameters on several hydrogel properties, including 
swelling degree, transparency, compressive strength, degradation rate, 
as well as cellular adhesion and proliferation. Based on the current 
knowledge on PAAs, both the ABG/BAC ratio and the Michael-type 
addition reaction time affect the average molecular weight of the PAA 
oligomers [10].  These oligomers were further reacted by radical 
polymerization to achieve hydrogels. The PAA oligomers' average 
molecular weight affected in turn surface chemistry and mesh size of the 
resulting hydrogels. The HEMA concentration in the polymerizing mixture 
was found to influence different features such as hydrophilicity, 
transparency and mechanical properties. The UV-induced 
photopolymerization was found to be successful in the preparation of 
OPAA and OPAH series, whereas PAA and PAH were obtained by redox-
initiated polymerization. The photo-induction was ineffective for the latters 
probably because of the lower transparency of the starting liquid mixture. 
The synthesized hydrogels showed generally high versatility and excellent 
resistance to mechanical stress during washing steps, resulting in a 
faster washing process compared to reference PAA hydrogel. However, 
the hydrogel transparency was inversely proportional to the (HEMA + 
unreacted BAC)/PAA oligomers weight ratio before the radical 
polymerization step. This can be addressed to the phase separation 
following the appearance of acrylic chains in the polymerizing mixture 
[34]. We carried out a characterization of the mechanical properties by 
compressive strength measurement of selected samples representing the 
four studied hydrogel series in comparison with the reference PAA 
hydrogel. Thanks to the inherent mechanical properties of the acrylic 
chains within the polymer network, PAA-based hydrogels showed 
enhanced compressive strength and deformation capacity compared with 
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the reference PAA hydrogel. In particular, PAA and PAH hydrogels showed 
higher rupture load, whereas OPAA and OPAH displayed a much higher 
rupture strain compared to the reference PAA hydrogel, that is 
addressable to cross-linking density, which is, respectively, higher in the 
former and lower in the latter [35]. The equilibrium swelling degree was 
found inversely proportional to the HEMA/(BAC+ABG) ratio, due to the 
lower hydrophilicity of PHEMA chains. To assess the correlation between 
the acrylic-PAA chain balance and the degradability of the hydrogel, 
degradation tests of selected hydrogels representing the four studied 
series were carried out in physiologic environment at 37 °C. The 
degradation rate was found to be linearly dependent on the ratio of acrylic 
to PAA chains. Indeed, the higher the number of acrylic (i.e., non 
degradable) chains, the lower was the degradation rate. Accordingly, PAA 
and PAH hydrogels were characterized by lower degradation rate 
compared to OPAA and OPAH hydrogels. The mechanical and degradation 
tests demonstrated that it is possible to achieve a fine control of both 
compressive strength and degradation rate by varying the amount of BAC 
reacted in the radical polymerization. According to these results, the 
synthesized PAA-based hydrogels can match the requirements of different 
in vitro and in vivo applications, such us cell culture substrate, 3D matrix 
for tissue engineering and controlled drug release. Finally, extensive in 
vitro adhesion and proliferation tests with MDCK cells were carried out to 
correlate the biological properties with the investigated physico-chemical 
parameters. In particular cell proliferation onto the PAA-based hydrogels 
was up to 208% compared to glass control. By comparing the 
proliferation efficiency with the theoretical r ratio, it was evident that 
hydrogels with lower ABG/BAC ratio, showed better biological properties. 
This cellular response could be mainly due to the surface chemistry 
variation, with the contribution of stiffness variation. In fact, hydrogels 
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with higher cross-linking degree, which, at fixed ABG/BAC ratio, is higher 
for lower Michael-type addition reaction time, showed a poorer cellular 
proliferation. Interestingly, the presence of increasing concentration of 
HEMA did not result in decreased cell adhesion, despite the anti-fouling 
properties of PHEMA toward proteins, that could hinder the formation of 
an adequate protein substrate for cell adhesion [36]. This outcome 
enables the variation of HEMA concentration in PAA hydrogels to adjust 
transparency and mechanical properties, without hampering the optimal 
performances as substrate for cell culture.  
 
 
Table 3. Final assumptions on the observed correlations between the reaction parameters 
and the studied physico-chemical and biological properties. The symbol "!" indicates 
direct proportionality; the symbol """ indicates inverse proportionality; the symbol "✕" 
indicates that no linear relation could be determined between the variables. 
 
The morphology after 48 hours of cells cultured on PAA and PAH 
hydrogels was similar to the control, whereas cells cultured on OPAA and 
OPAH were smaller and round shaped despite showing high proliferation. 
This could be explained by considering the difference in substrate 
stiffness between OPAA/OPAH and PAA/PAH hydrogels, that affects the 
cells spreading to the hydrogel's surface [37]. The complex inter-relation 
of monomers' ratios and reaction time with mechanical properties, 
Compressive 
Strength Transparency
Degradation 
rate
Swelling 
degree
MDCK 
Proliferation
PAA/PAH
   - r  (ABG/BAC ratio)     
   - reaction time     ✕
- HEMA/ (BAC+ABG) ratio     ✕
OPAA/OPAH
   - r (ABG/BAC ratio)     
- HEMA/(BAC+ABG) ratio     ✕
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transparency, degradation rate, swelling degree and cellular proliferation 
are shown in Table 3.  
 
5. Conclusions 
The aim of the present study was to investigate the correlation of 
selected synthetic parameters such as monomer ratio, Michael-type 
addition reaction time and presence of various amounts of HEMA, to the 
physico-chemical and biological properties of the PAA-based hydrogels in 
order to develop a versatile platform for tissue engineering. Four series of 
innovative, biodegradable and biomimetic hydrogels based on 
poly(amidoamine)s with tailorable mechanical properties and degradation 
rate were successfully designed, synthesized and characterized. The 
introduction, through free-radical polymerization, of acrylic chains in the 
PAA macromolecular network improved cell adhesion and allowed the 
control of their mechanical properties and degradation rate. Even though 
the presence of PHEMA chains (up to 30%mol) in the PAA 
macromolecular network did not influence the adhesion and proliferation 
ability of the hydrogels, it was found to affect the swelling degree, the 
degradation rate and the mechanical properties, as well as to improve the 
transparency. Tailoring the swelling behavior may be useful for the 
application of PAA-based hydrogels as sensors or in microfluidics. Thanks 
to their mechanical properties, the PAA and PAH hydrogels seemed more 
suitable for in vitro culture and research purposes, whereas the OPAA and 
OPAH hydrogels would be more useful for in vivo applications as well as 
for cell encapsulation and hydrogel 3D printing applications, due to the 
mild conditions of the photopolymerization process and the higher 
degradation rate. Our results show that this class of hydrogels represents 
a very promising platform for the development of biomaterials and 
technologies for Tissue Engineering applications.  
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1. Introduction 
In recent years three-dimensional (3D) cell culture is receiving increased 
attention as a tool for in vitro biological experimentation [1]. In fact, 
researchers come to appreciate the different biological response between 
cells cultured in monolayer and 3D cell culture, more consistent to the 
environment in which cells physiologically operate [2,3]. In particular, as 
the complex relationships between cells and the extracellular matrix 
(ECM) in vivo plays a critical role in controlling their behavior and 
functioning [4], great efforts have been made to design synthetic ECMs, 
able to mimic the properties of the natural 3D cellular milieu, ensuring 
that cells cultured in vitro behave similarly to their counterparts in vivo 
[5]. The potential of 3D cell culture approach to create in vitro models, for 
toxicity/drug screening and disease or cellular studies [6,7], has 
encouraged the development of materials with controllable biological, 
chemical and mechanical properties [8,9], that are also able to 
recapitulate natural ECM microstructures, with the ultimate goal of 
achieving a precise control over cellular and tissue functions [5,10-13]. 
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To this aim hydrogels have emerged as desirable biomaterial systems for 
guiding 3D cell behavior to specific functions [14]. Hydrogels offer 
numerous advantages such as high water content and biocompatibility. 
Naturally derived molecules were commonly used to create cell-laden 
hydrogels owing to their intrinsic bioactivity, biocompatibility, and 
biodegradability. In particular, cell-laden hydrogels have been created 
from a wide variety of native ECM molecules, including collagen [15], 
fibrin [16] [17], hyaluronic acid [18,19], Matrigel [20,21], and gelatin 
[ 22]. These biomolecules naturally contain cell-signaling attributes that 
enable high cellular viability and proliferation. Nevertheless, the same 
cues that allow cells to prosper in these materials are so abundant that 
become challenging to precisely control and assess their effects on 
cellular behavior. In addition, batch-to-batch variability generates 
hydrogels whose physico-chemical properties are difficult to reproduce 
and engineer [5]. This results in modest mechanical properties and in the 
inability to control their microarchitecture, limiting their use in the 
creation of durable cellular constructs. On the other hand, synthetic 
polymer-based hydrogels, in which the chemical and biophysical 
properties of the cell microenvironment can be easily tuned [8, 9, 12-14], 
are becoming increasingly attractive as 3D culture platforms. 
Poly(ethylene glycol) (PEG) is considered the gold standard for synthetic 
hydrogels thanks to its high hydrophilicity and its inert network resistant 
to protein adsorption [4,11]. However, the lack of cell-responsive features 
resulted in its inability to promote cellular proliferation and mobility, 
crucial for the creation of 3D organized cellular constructs. Modifications 
with binding motif Arg-Gly-Asp (RGD) [23-25], or physical mixing with ECM 
components [19], have been presented to increase cell adhesion and 
proliferation. PEG hydrogels, containing both cell binding RGD motifs and 
matrix metalloproteinase (MMP)-sensitive degradation regions [26-33], 
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have been shown to promote cell elongation, migration and 
interconnection in vitro with different cell lines. Their main drawback lies 
in the use of peptide sequences, which contribute to increase the cost 
and complexity of the synthesis and may weaken their micropatterning 
ability in comparison to unmodified photopolymerizable materials [22]. 
For these reasons, the use of PEG hydrogels is still limited to the creation 
of microscale in vitro tissue.  
Another promising class of synthetic polymers for cell culture applications 
are poly(amidoamine)s (PAAs) [34]. They are obtained by Michael-type 
addition of bis-acrylamides to primary amines and/or secondary 
diamines, under mild conditions. Different bioactive molecules can be 
incorporated in the PAA's backbone by covalent attachment during the 
synthetic process [35-37]. PAA-based hydrogels show good 
biocompatibility and are extremely versatile, being easily modifiable by 
introducing different comonomers that carry additional chemical functions 
such as carboxylic acids, thiols and amino groups [38-43].  In order to 
improve cell adhesion properties of PAA hydrogels, Ferruti and co-workers 
developed an RGD-mimetic PAA with a repeating unit constituted by 2,2-
bisacrylamidoacetic acid (BAC) and 4-aminobutylguanidine (ABG, 
Agmatine) [44]. The introduction of ABG units in a cross-linked 
amphoteric PAA hydrogel resulted in an increased fibroblast cell 
adhesion. However, PAA hydrogels displayed some drawbacks such as 
non-controllable degradation rate, poor mechanical properties and high 
risk of ruptures during washing due to osmotic pressure. Since it has 
been demonstrated that the ABG residue in PAA hydrogels maintains cell 
adhesion by promoting this ability even when copolymerized with other 
monomers, we supposed that, by copolymerizing the PAA-based ABG with 
Jeffamine®, it would be possible to obtain a hybrid hydrogel with optimal 
cell-adhesion and mechanical properties, avoiding the use of the 
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expensive RGD peptide. In this study, the synthesis of a new 
photocrosslinkable, biomimetic PAA-Jeffamine-PAA triblock copolymer 
(OAPAO) hydrogel is presented and its physico-chemical properties are 
extensively discussed. OAPAO hydrogel surface and 3D cell encapsulation 
behavior were deeply investigated. Additionally cell-laden OAPAO 
hydrogels were patterned with perfusable microchannels and seeded with 
endothelial cells, to investigate the potential use of OAPAO gels for micro 
tissue engineering applications. 
 
2. Materials and Methods 
 
2.1  Materials 
4-aminobutylguanidine sulfate (ABG, agmatine), ammonium persulfate 
(APS), O,O′ - Bis (2 -aminopropyl) poly(propylene glycol)-block-poly(ethylene 
glycol)-block-poly(propylene glycol) with molecular weight of 600, 900 and 
2000 (Jeffamine® 600, 900 and 2000, respectively), Poly(ethylene 
glycol) diacrylate 4000 (PEGDA), 2-hydroxy-1-(4-(hydroxyethoxy)phenyl)-2-
methyl-1-propanone (Irgacure 2959, CIBA Chemicals),! Dimethyl sulfoxide 
(DMSO), lithium hydroxide monohydrate (LiOH), hydrochloric acid (HCl), 
trichlorododecylsilane (TCS), and tetramethylethylenediamine (TEMED), 
sodium chloride (NaCl), sodium phosphate dibasic (Na2HPO4), potassium 
phosphate monobasic (KH2PO4) were purchased from Sigma-Aldrich at the 
highest degree of purity available and used as received. Milli-Q grade 
water was used in all the experiments. Phosphate buffered saline (PBS) 
used in the experiments contained 2.69 mM KCl, 136.89 mM NaCl, 3.21 
mM Na2HPO4, 1.47 mM KH2PO4. Finally, 2,2-bis(acrylamido)acetic acid 
(BAC) was prepared as previously reported and its purity (99.9%) 
determined both by acid-base titration and by NMR spectroscopy [45].  
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2.2  Glass slides silanization and molds fabrication. 
Glass slides were silanized for fabricating cylindrical molds. Briefly, glass 
slides were washed with acetone, activated by plasma oxygen (70 W, 70 
s) and immersed in a TCS solution (5% v/v in petroleum ether) for 10 
minutes. Afterwards, glass slides were washed in succession with 
petroleum ether and ethanol, dried with gentle air flow and stored at room 
temperature. Molds were then prepared by interposing between two 
silanized glass slides a preformed silicone spacer (0.3 and 1 mm thick). 
Into the preformed silicone spacers were previously cut void circles of 
internal diameter of 10 and 15 mm, respectively. The mold for 
microfluidic experiment was fabricated in a similar manner using two 
preformed silicone spacer of 1 mm thickness, cut to obtain a rectangular 
void area of 15X5 mm. In a different experimental setup a needle of 300 
µm was placed between the two spacers. 
 
2.3  PAA Oligomer synthesis 
In a 50 mL round-bottom flask, BAC (200 mg, 1.0 mM), water (333 µL), 
lithium hydroxide (48.8mg, 1.14 mM) and ABG (for OPAA-2: 168.8 mg, 
0.717 mM; for OPAA-4: 199.4 mg; for OPAA-6: 210.7 mg) were added in 
this order and the resulting mixture was stirred at 35°C for 7 days in the 
dark and under inert atmosphere. Afterwards, the mixture was diluted 
1:50 with bi-distilled water and brought to pH 4.0 through addition of 
concentrated hydrochloric acid. The resulting solution was purified from 
unreacted BAC by ultrafiltration on membrane with a cut-off of 1000 
(OPAA-2) or 3000 (OPAA-4 and OPAA-6) and subsequently freeze-dried 
(Telstar Cryodos 50). Yield: OPAA-2, 88%; OPAA-4, 82%; OPAA-6, 86%. 
GPC data: OPAA-2, Mn = 2100, d = 1.31; OPAA-4, Mn = 4300, d = 1.25; 
OPAA-6, Mn = 6400, d = 1.35. 1HNMR spectra of all the synthesized 
oligomers showed the following characteristic peaks: 1H NMR (400 MHz, 
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D2O, 25°C, δ): 1.55 (br, NHCH2CH2CH2), 1.71 (br, NHCH2CH2), 2.74 (br, 
NHCOCH2CH2), 3.13 (m, NHCH2, NCH2), 3.39 (br, NHCOCH2), 5.51 (s, 
CHCOOH). 
 
2.4  OAPAO oligomer synthesis 
OAPAO diacrilamide terminated oligomers were synthesized by Michael-
type addition of PAA to Jeffamine. In brief, in a 5 mL cuvette, PAA 
oligomers (600 mg, 0.3 mmol) water (884 µL), Jeffamine (for OAPAO-4, 
Jeffamine 500, 50.0 mg, 0.1 mmol; for OAPAO-5, Jeffamine 800, 80.0 
mg, 0.1 mmol; for OAPAO-6, Jeffamine 2000, 195.0 mg, 0.1 mmol) and, 
only in the case of OAPAO-5 and OAPAO-6, 250 µL of ethylene glycol were 
added to improve reagents solubility. The pH of the resulting mixture was 
brought to 10.5 by addition of LiOH. The reactant solution was stirred at 
35 °C for 24 hours under inert atmosphere and in the dark. The solution 
was then diluted 1:50 with bi-distilled water, acidified to pH 7.0 with a 
few drops of HCl (37 %), ultrafiltrated (5000 Da cut-off membrane) and 
freeze-dried. Yield: OAPAO-4, 87%; OAPAO-5, 70%; OAPAO-6, 57%. 
 
2.5  Hydrogel preparation and characterization 
Freeze-dried OAPAO and PEGDA oligomer was mixed into PBS. Irgacure 
2959 (1000 mg/ml in 100% DMSO) was added, as a photoinitiator, to 
the hydrogel pre-polymer solution to yield final concentrations of 0.5% 
(w/v). The reacting mixture was stirred for 1 min, injected in the glass 
mold and photopolymerized by exposure to UV light (365 nm, 10 
mW/cm2) for 3 min. Then the hydrogels were recovered from the mold.  
 
2.6  Chemical characterization 
Size exclusion chromatography (SEC) traces of PAA-based polymers were 
obtained with Toso-Haas 486 columns using 0.1 M Tris buffer pH 
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8.00±0.05 as a mobile phase, with a UV detector operating at 230 nm. 
The molecular weight determination was based on pullulan standards. 
Proton nuclear magnetic resonance (1HNMR) spectra were run on a 
Bruker Advance 400 spectrometer operating at 400.132 MHz. Fourier-
transform infrared spectroscopy (FTIR) spectra of dry hydrogel samples 
were measured using a Jasco ATR-FTIR 300 spectrophotometer.  
 
2.7  Mechanical characterization. 
The compressive strength was measured using a testing machine 
equipped with a 100 N load cell (EMT503A, MP Strumenti, Pioltello (MI), 
Italy). Each measurement was run six times at 20 °C and 60 % relative 
humidity. Axial load was applied with a crosshead constant speed of 1 
mm/min. The hydrogels were prepared 15 % (w/v) concentration by 
injection molding into 12 mm diameter, 7 mm height cylinders.  
 
2.8  Swelling test 
Hydrogels cylindrical samples, having 1.5 cm diameter and 0.3 cm 
thickness, were previously dried at 20 °C and 0.1 Torr. Their weight was 
40 mg ± 2 mg. Each specimen was placed inside a 10 mL tube 
containing 5 mL PBS (pH 7.0), incubated at 37 °C and weighed at regular 
intervals. The uptake of water was measured until the maximum mass 
was obtained. The percent amount of water absorbed was calculated 
using the following formula: 
Swelling (%) = Wwt / Wd × 100, (1) 
where Wwt is the water mass absorbed at time t and Wd is the mass of 
the dry sample at time zero. 
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2.9  Degradation test 
Hydrogels cylindrical slabs having 1.5 cm diameter and 0.3 cm thickness, 
were placed inside a 10 mL test tube containing 5 mL PBS (pH 7.0) and 
incubated at 37°C. At fixed time point they were freeze-dried and 
weighed. The percent degradation was calculated using the following 
formula: 
Degradation (%) = Wf / Wd × 100, (2) 
where Wf is the dry weight at time t, Wd is the mass of the dry sample at 
time zero. 
 
2.10  Cell culture 
NIH 3T3 murine embryonic fibroblasts (CRL-1658, ATCC, Manassas, 
Virginia) were kept at 37ºC in 5% CO2 98% air-humidified incubator. The 
cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS), 2 mM L-Glutamine, 
100 units/ml penicillin and 100 µg/ml–streptomycin. Once 80% 
confluent, the 25-cc flasks were passaged (subculture ratio 1:4 for 
multiple flasks) every 2-3 days for both experiments. Human umbilical 
vein endothelial cells (HUVECs) were obtained from PromoCell Gmbh 
(Heidelberg, Germany). The cells were cultured in M199 medium 
supplemented with 2 mM L-Glutamine, 100 units/ml penicillin and 100 
µg/ml–streptomycin and freshly added with 20% FBS, 50 ng/ml ECGF and 
100 µg/ml Heparin. In microfluidic experiments stable GFP expressing 
HUVECs (Pelobiotech, US) were used. They were perfused with 
endothelial cell growth media EBM-2 (Lonza) supplemented with EGM-2 
singleQuot Kit Supplemets and Growth (Lonza), and they were used 
through passage 8. All products were purchased from Sigma Aldrich 
unless otherwise specified.  
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2.11  Cell adhesion 
2-D cell culture on hydrogel discs. 
3T3 and HUVEC (cell density: 104 cells/cm2) cells were seeded on UV-
sterilized hydrogel discs containing multiwell plate (24-48 wells) and 
incubated at 37°C in 5% CO2 and 98% air-humidified. Cells were cultured 
for 24-48 h monitoring their growth with an inverted phase contrast 
microscope (Leica micro systems, Germany) equipped with a digital 
camera Leica DFC 295.  
 
Cell attachment/spreading assay. 
After 48h hydrogels discs cells were washed with PBS solution, fixed with 
4% paraformaldehyde 15 minutes at room temperature, washed again 
with PBS and finally stained with BisBenzimide H 33258 (Hoechst) 5 
µg/ml. Than, fluorescent nuclei digital images were collected with a Leica 
SP5 confocal microscope (5 fields for disc, 10x magnification zoom 2) 
and their number was measured by ImageJ software. 
 
Fluorescence staining  
After 48 h in culture, cells were fixed in situ with 4% paraformaldehyde, 
rinsed with PBS, permeabilized with 0.1% Triton X-100, blocked with 2% 
BSA and then incubated with Alexa fluor 555 directly conjugated to 
phalloidin, 0,11uM, (Invitrogen, Inc., Eugene, OR) for 40 min at room 
temperature for filamentous actin staining. After washing in PBS, cells 
were stained with Hoechst, 9.4uM. Images were captured along the 
channel length and channel depth (at 0.2–0.5mm depth intervals) using a 
Leica SP5 confocal microscope. All scaffolds were imaged through the 
glass cover slip wall. HUVEC cultured on gelatin-coated glass served as 
positive control. 
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2.12  Cell encapsulation 
Murine fibroblasts were trypsinized, counted and suspended within 
PEGDA, OPAA-2 and OAPAO macromer solution containing 0.5% (w/v) 
photoinitiator at a concentration of 5x106 cells/mL. Different macromer 
concentrations (5, 7.5, 10, 15% w/w) were tested. The cell-macromer 
solution was injected in the glass mold and photopolymerized by 
exposure to long-wavelength UV light (365 nm, 10 mW/cm2) for 1 min. 
Agarose gel was used as a control. In this case low-melting point agarose 
was dissolved in sterile PBS (pH 7.4) to yield a final concentration of 
2.5% (w/v) and heated to 70°C. NIH 3T3 fibroblasts were trypsinized, 
counted and suspended within the agarose solution at 5x106 cells/mL 
that was cooled to ~42ºC and pipetted to ensure even cell distribution. 
Agarose solution was injected in the glass mold and cooled to 4°C for 20 
min. Hydrogels were then recovered from the mold and incubated in 
DMEM under standard culture conditions. Media was changed every 48 h. 
Murine fibroblast viability within the microgels was quantified by live/dead 
fluorescence assay (Calcein AM/Propidium Iodide, Life Technology) at 
different time points (0, 24, 48hours) 
 
2.13  Microfluidic cell-laden hydrogel fabrication  
To create perfusable microchannels, 200 mL of 15% (w/v) OAPAO-4 with 
1% (w/v) of photoinitiator and containing 2x106 cells/mL (NIH 3T3) was 
injected in the mold described in section 2.2. The mixture in the mold 
was evenly photopolymerized by exposure to long-wavelength UV light 
(365 nm, 10 mW/cm2) for 1 min. The rectangular gel was then demolded 
and the needle was gently withdrawn. Perfusion studies were performed 
using fluorescent nanoparticles (Latex beads, amine-modified 
polystyrene, fluorescent blue aqueous suspension, 0.05 µm mean 
particle size) and connecting the microfluidic gel to a peristaltic pump 
Chapter 3 
 
! !
Page 49 !
with small silicon tubing to enable perfusion. For cell perfusion 
experiments, 20 µl GFP-HUVECs suspension (5x106 cells/ml) was 
injected into the channel. Microfluidic gels were immersed in media and 
placed at standard cell culture conditions. To perform a dual-color live 
imaging labeled 3T3 cells were used and constructs were visualized with 
Leica SP5 confocal microscope incubator equipped. 
 
2.14  Statistical Analysis 
Each hydrogel type was tested at least 5 times with similar results. All 
data are expressed as 100*sample arithmetic mean/control arithmetic 
mean ± S.E.M.. Significance of differences was determined using 
Student’s t-test (p<0.05). 
 
3. Results 
 
3.1  Hydrogel preparation 
Diacrylamido-terminated PAA oligomers with average molecular weight of 
2000 (OPAA-2), 4000 (OPAA-4) and 6000 Da (OPAA-6) were synthesized 
by Michael-type addition between BAC and ABG and subsequently purified 
by ultrafiltration and freeze-drying.  In order to obtain an OPAA-Jeffamine-
OPAA triblock copolymer with different molecular weights and terminated 
with acrylamide functions, the synthesized PAA oligomers were coupled 
through Michael-type addition with Jeffamine (Fig. 1). The coupling 
reaction successfully occurs only when OPAA-2 was coupled with 
Jeffamine. In fact, mixtures of Jeffamine with OPAA-4 and OPAA-6 allowed 
poor coupling reaction resulting in phase’s separation in a wide pH and 
temperature range. Three different triblock copolymers (OAPAO-4, OAPAO-
5 and OAPAO-6) with molecular weight of 4600, 4900 and 6000 Da, 
respectively, were produced. After ultrafiltration and freeze-drying, the 
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final triblock oligomer was photopolymerized through free-radical 
polymerization to yield degradable hydrogels for cell encapsulation with 
RGD-mimetic monomeric units. 
 
 
 
Figure 1. Synthetic scheme of the triblock diacrylamido-terminated (OAPAO) oligomer: a) 
water, 30°C, pH 9, inert atmosphere, 72h; b) water, 30°C, pH 10.5, inert atmosphere; 
24h. 
 
3.2  Mechanical properties 
Mechanical properties of the extracellular environment have been shown 
to affect cell function and differentiation. To determine the effect of the 
oligomer’s molecular weight on the mechanical properties of the OAPAO 
hydrogels, unconfined compression was performed on hydrogels of 
OAPAO-4, OAPAO-6 and the control PAA oligomers at the fixed 
concentration of 15% w/w. In general, increasing the molecular weight of 
the starting oligomer decreased stiffness and compressive modulus, due 
to lower crosslinking density. As illustrated in Figure 2a, hydrogels 
obtained from OAPAO are characterized by higher compressive elastic 
modulus (E’) than those obtained from diacrylamide-terminated PAA 
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oligomers of the same average molecular weights. Such a characteristic 
is much evident in the case of OAPAO-4 hydrogels, where the elastic 
modulus was five times higher than the control hydrogel obtained from 
OPAA-4 oligomers. Following the same tendency, load failure was found to 
be higher for OAPAO-4 hydrogels (9.2 N) than OPAA-4 control (3.5 N). The 
enhanced elastic behavior of OAPAO hydrogels, compared to the control, 
underline the role that PEG segments play in the contrast of non-covalent 
interaction among PAA macro-domains, which is the main reason for PAA 
hydrogels fragility. 
 
 
Figure 2. Compressive modulus (a) and stiffness (b) of the synthesized hydrogels. Error 
bars represent the SD of measurements performed on at least 3 samples.  
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3.3  Swelling and Degradation characteristics 
The swelling characteristics of a polymer network are important in various 
applications as they affect solute diffusion, surface properties, 
mechanical properties, and surface mobility. The degree of gel swelling is 
dependent on the pore size of the polymer network and the interaction 
between the polymer and the solvent. As hydration can have a substantial 
effect on the physical properties of the resultant hydrogel, e.g. the 
replication fidelity of the desired micropattern, the change in the mass to 
swelling ratio of OAPAO was investigated relative to the hydrogel 
concentration. Hydrogels were made as described previously at 15% (w/v) 
OAPAO. Hydrogels were allowed to reach equilibrium over a 24 h 
incubation period in PBS at room temperature, then the mass swelling 
ratio of the swollen mass to the dry mass of polymer and the degradation 
rate in PBS at 37°C was calculated. Measured mass swelling ratio was 
264 ± 2% for OPAA-2, 405 ± 5% for OAPAO-4 and 380 ± 5% for OAPAO-6. 
These data shows a higher mass to swelling ratio of OAPAO compared to 
OPAA-2, demonstrating that the conjugation Jeffamine had a significant 
effect on the material’s ability for storing water within the polymer 
network. The degradation rate was higher for OAPAO hydrogels than for 
control OPAA-2 hydrogel, consistently with the higher swelling ratio of the 
studied polymers (Fig. 3). The degradation rate was found to increase 
with the oligomers' average molecular weight. In fact, among the OAPAO 
hydrogels, OAPAO-4 showed the highest rate of degradation reaching 45% 
of weight loss after approximately 120 days.  
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Figure 3. Degradation curves of 15% (w/v) OAPAO-4 (squares), OAPAO-6 (diamonds) and 
control OPAA-2 hydrogels (triangles). 
 
3.4  3T3 Cell adhesion to 2D OAPAO surfaces 
The ability of a scaffold to promote cell binding strongly affects cell 
behavior and is an essential requirement in tissue engineering [46]. In 
order to validate the use of OAPAO hydrogels for potential application in 
tissue engineering, we measured their cell adhesion properties using 
murine fibroblasts as a model cell type. Fibroblast adhesion was 
determined on different OAPAO hydrogels fixing the concentration at 15% 
(Fig. 4a) and 30% (w/v) (Fig. 4b) and varying the macromer molecular 
weight or increasing the concentrations at 7.5%, 10%, 15%, and 30% 
(w/v) at fixed molecular weight (Fig. 4c). Changes in the molecular weight 
of the OAPAO macromer was obtained by combining Jeffamine with 
increasing molecule weight to the same PAA oligomers. Cell adhesion 
was also investigated on pure PAA oligomers, PEGDA hydrogel and glass. 
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Pure PAA and PEDGA hydrogels represented, respectively, the highest 
concentration and the absence of RGD-mimetic sites. Glass was used as 
positive control. 3T3 readily bound to OAPAO surfaces of all 
concentrations with roughly the same affinity following initial seeding but 
after 48h some differences emerged. In Figure 4a is shown that OPAA-2 
had the best adhesiveness as expected for the RGD-mimetic binding 
sites abundance (more than 3 times compared to glass) followed by 
OAPAO-4 and OAPAO-5 (more than 2 times compared to glass) and 
OAPAO-6 (almost comparable to glass). As expected, few cells adhered to 
PEGDA surfaces, as PEG is not cell adhesive, and adhesion was observed 
to decrease over time (results not shown). Doubling macromer 
concentration of OAPAO-4 from 15% to 30% (w/v) improved the 
performances showing the best result on OAPAO hydrogels (Fig. 4b). 
Interestingly, OAPAO-5 was prevented in its performance and decreased 
to glass control values. In order to better evaluate the performances of 
OAPAO-4 we measured cell adhesion at different OAPAO concentration 
(Fig. 4c). This experiment showed that OAPAO-4 has much better or at 
least the same performance as control glass in all the concentrations 
tested. Overall, these results confirmed that OAPAO-4 is best hydrogel for 
2D cell culture. 
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Figure 4. Cell proliferation values of 3T3 cells cultured for 48h on 2D hydrogels using 
glass slide as a control. The symbol “” represents statistical significance by students T-
test (p<0.05), comparing each sample against the control (GLASS).  
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3.5  HUVECs Cell adhesion to 2D OAPAO surfaces 
Surface adhesion characteristics of OAPAO-4 were determined at 7.5%, 
10%, 15%, and 30% (w/v) OAPAO-4 concentration (Fig. 5). The 4000 
molecular weight was chosen as this formulation performed best in 3T3 
cell adhesion experiments. HUVECs were chosen as a model cell type for 
potential application of OAPAO in vascularized tissue engineering, as well 
as to explore the compatibility of OAPAO with a human cell type.  
 
 
 
 
 
Figure 5. (a) Cell proliferation values of HUVECs cultured for 48h on 2D hydrogels of 
increasing OAPAO-4 concentration. The symbol “” represents statistical significance by 
students T-test (p<0.05), comparing each sample against the control (C-GLASS). Confocal 
microscopy images of HUVECs conformation on OAPAO-4 at 15% (b) and 30% (w/v) (c) on 
glass (d) and (scale bar, 20µm). 
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Cells on OAPAO surfaces 15% and 30% attached and proliferated better 
than control, whereas on 10% and 7.5% less cells were found but still 
with a good morphology and viability (Fig. 5). Significant differences in the 
cell density, defined as the number of Hoechst positive cells per fixed 
area, demonstrated that cell density significantly increased with 
increased OAPAO concentration. These differences in cell behavior are 
likely due to a combination of variations in the stiffness of the OAPAO 
surfaces relative to the gel concentration, and increases in the density of 
bioactive sequences with increased macromer concentration. 
 
3.6  3D cell encapsulation in OAPAO 
To further demonstrate the use of OAPAO as a hydrogel for tissue 
engineering application, encapsulated cell behavior was studied within 
OAPAO hydrogel. In these experiments NIH 3T3 fibroblasts were 
encapsulated in 0.3 mm thickness and 10 mm diameter slab of OAPAO-4 
at concentrations of 5%, 7.5%, 10% and 15% (w/v). OAPAO-4 gels 
performed similarly to PEG in terms of pattern replication accuracy and 
UV exposure time (data not shown). Viability at 4 h after encapsulation 
was 94 ± 1% in 5% OAPAO and 92 ± 1% in 7.5%, which were slightly 
higher than that in 10% (91% ± 1%) or 15% (91% ± 1%) (w/v) microgel 
samples. Initial viability was similar to that exhibited in agarose hydrogels 
(89 ± 3%), demonstrating that UV polymerization and micropatterning did 
not considerably alter cell viability. Consistently with these data, in 
previous works cell viability has been shown to decrease with macromer 
concentration in other hydrogel matrices [11,47]. This viability loss is due 
to encapsulation stress, nutrient limitations and swelling stress after 
polymerization. This behavior is more evident at 24 h when the viability 
was 85 ± 3% in 5% OAPAO-4 and 83 ± 3% in 7.5% OAPAO-4, which was 
higher than that in 10% (79% ± 3%) and 15% (72% ± 2%) (w/v) microgel 
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samples. Evolution of cell viability in bulk OAPAO until 15% was similar to 
the viability of agarose gel at all the time point whereas at more 
increased concentration showed reduced cell viability (Fig. 6f and g). 
 
Figure 6. Characterization of encapsulated cell behavior. 3T3 fibroblasts embedded in 
OAPAO-4 at 5% (a), 7.5% (b), 10% (c), 15% (d) (w/v) and in agarose (e) microgel were 
stained with live/dead assay at 48 hours after encapsulation. Quantification of 
encapsulated cells cell viability for different OAPAO-4 concentration, at 48 hours (f) and 
different time points and fixed concentrations (g), demonstrated excellent cell survival at 
all conditions, compared to agarose. The symbol “” represents statistical significance 
by students T-test (p<0.05), comparing each sample against the agarose control. Error 
bars represent the SD of averages obtained on 4 images from each of 6 independent 
samples per condition.  
 
3.7  Endothelialized microfluidic channels in cell-laden OAPAO hydrogel. 
To investigate the use of OAPAO for the creation of complex cell laden 
microengineered construct, labeled NIH 3T3 fibroblasts were embedded 
within microfluidic bulk OAPAO-4. In particular the mixture, containing 
a 
b 
d 
e 
c 
0% 
20% 
40% 
60% 
80% 
100% 
OAPAO-4 5% OAPAO-4 7.5% OAPAO-4 10% OAPAO-4 15% AGAR 2,5% 
C
el
l V
ia
bi
lit
y 
f 
★!
0% 
20% 
40% 
60% 
80% 
100% 
0 24 48 0 24 48 
C
el
l V
ia
bi
lit
y 
OAPAO-4 10%                                            AGAR 2.5% 
g 
Chapter 3 
 
! !
Page 59 !
cells and macromers, was polymerized around a syringe needle, which, 
when removed, created a 300 µm perfusable channel in a cell-laden 
matrix (Fig. 7). In these experiment OAPAO-4 was used at 15% w/v 
concentration to reach an optimal compromise between encapsulated 
murine cell viability and HUVECs adhesion also ensuring enough gel 
stiffness needed for the perfusion of the microfluidic channel. Fluorescent 
nanoparticles were injected within the microchannel to demonstrate the 
ability to create defined microfluidic pathways within cell-laden OAPAO 
construct.  
 
 
 
Figure 7. Optical (left) and confocal (right) images at 24h of endothelialized microfluidic 
channels in cell-laden OAPAO. Channels were created in OAPAO containing 3T3 fibroblasts 
(red) and seeded with GFP-HUVEC (green) cells demonstrating the ability to create cell-
laden hydrogels with endothelial-lined, perfusable microvasculature (scale bar 500 µm). 
 
To demonstrate the ability to create cell-laden structures with 
endothelialized microchannels, GFP-HUVECs were seeded into the 
channel of microfluidic OAPAO cell-laden hydrogel and allowed to adhere, 
as described in section 2.13. The microfluidic cell-laden gel was able to 
support HUVECs attachment, spreading and function also when externally 
perfused. The coculture of encapsulated 3T3 cells and HUVECs seeded 
on the surface of microchannel demonstrates the potential for making 
complex engineered microtissue with perfusable vascular networks. 
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4. Discussion 
In this work, photo-crosslinkable PAA-based oligomers were synthesized 
as precursors of matrices for 3D cell culture and the physico-chemical 
and mechanical properties were studied in correlation to cell viability and 
proliferation with HUVECs cells in 2D (culture on hydrogel) and with NIH 
3T3 fibroblasts in 2D and 3D (encapsulation) and their combination in a 
co-cultured construct. The produced oligomers contained the ABG-BAC 
monomeric unit, which acts both as an RGD-mimetic site and as a 
hydrolytically degradable function. These functions were inserted in 
diacrylamide-terminated oligomers able to yield soft hydrogels by 
photopolymerization compatible with the presence of cells. The oligomers 
used to obtain the studied hydrogels were synthesized through Michael-
type addition of PAA and Jeffamine oligomers of selected molecular 
weight. In particular, PAA oligomers with molecular weights of 2000, 
4000 and 6000 were tested for the Michael-type addition to Jeffamine. 
However, only the one type of PAA oligomer, OPAA-2, yielded the desired 
product, since shorter and longer PAA oligomers generated phase 
separation in presence of Jeffamine in water in a large temperature and 
pH ranges. The studied hydrogels were compared with the related 
products obtained by diacrylamido-terminated PAA oligomers, OPAA-2, 
OPAA-4 and OPAA-6. Compared to PAA-based control hydrogels, OAPAO 
hydrogels showed improved performances in terms of stiffness, storage 
and elastic modulus, equilibrium swelling ratio and degradation rate. In 
particular, extensive physico-chemical measurements revealed that the 
presence of Jeffamine segments in the PAA oligomer resulted into two 
main effects: (1) improvement of the mechanical properties, due to 
crystalline domains in the crosslinked network generated by Jeffamine 
segments increasing the hydrogel’s stiffness [48]; (2) Increased swelling 
ratio, due to intrinsic hydrophilicity of Jeffamine, that resulted in a higher 
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degradation rate able to improve the limited degradation ability of PAA 
crosslinked by free-radical polymerization [38]. 
This study confirmed the superior OAPAO adhesion performance in 2D 
compared to the glass control, for both NIH 3T3 and HUVECs. High cell-
binding properties are the result of RGD-mimetic binding sites abundantly 
present in the OAPAO macromer. OAPAO hydrogel was also employed for 
encapsulation of murine fibroblasts to form cell-laden hydrogels able to 
encourage cell viability in vitro. In particular, encapsulated cells showed 
cell viability comparable to the ones embedded in agarose gels. To our 
knowledge, this is the first study involving a 3D cell culture with a PAA 
based RGD-mimetic hydrogel. However, in all the encapsulation 
experiments cells did not migrate or degrade the OAPAO gels. This is due 
to the fact that OAPAO hydrogels are hydrolytically degradable, but lack of 
enzymatic degradation motifs. Without the possibility for cells to degrade 
and remodel the matrix, cell movement and organization in 3D is 
inhibited. In order to solve this limitation OAPAO hydrogels could be easily 
modified by incorporating protease-sensitive regions, similarly done in 
literature with PEG [26,28,31,33,49]. This will enable the use of OAPAO 
in most applications in which PEG has been successfully used, with 
comparable, or better performances as PEG containing cell binding and 
degradation motifs. Photopatterning ability of OAPAO was demonstrated 
in the fabrication of perfusable microfluidic channels. In these 
experiments OAPAO behaved similarly to PEGDA in terms of UV exposure 
time, fidelity and optical transparency. This indicates that OAPAO could 
potentially be used in most of the applications in which 
photopolymerizable PEG has been demonstrated in, with similar, or even 
better, performances. In order to demonstrate the potential of OAPAO in 
the creation of tissue-like structures, functional cells (NIH 3T3) were 
encapsulated in microfluidic OAPAO lined with endothelial cells (HUVECs) 
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and successfully characterized by confocal imaging. Cell-laden 
microvascular OAPAO has been shown to encourage cell-responsive 
behavior and surface binding. In the same experiment OAPAO hydrogels 
showed good mechanical stability when externally perfused (results not 
shown). Overall, these studies support the use of OAPAO hydrogels as 
tunable and inexpensive biomaterials for the creation of complex cell-
laden constructs with features controllable on the microscale. 
 
5. Conclusions 
In the present study we demonstrated, for the first time, the use of PAA 
for 3D cell culture applications, highlighting the unique properties that 
make OAPAO an attractive material for creating cell-laden micro construct. 
The physico-chemical properties of OAPAO were demonstrated to be 
controllable through the variation of the molecular weight and the gel 
concentration yielding a tunable range of mechanical, swelling and 
degradation properties for different applications. Similarly to other 
synthetic hydrogel, OAPAO was easily patterned to fabricate consistent 
cell-laden hydrogels that can be used as monolithic microfluidic device. 
Unlike other synthetic UV crosslinkable hydrogels, cells rapidly adhered 
and proliferated on OAPAO surface, remaining viable when encapsulated 
in 3D. Overall these data suggest that OAPAO could be used for many 
applications where other synthetic hydrogels are too expensive or not 
appropriate, such as for creating endothelialized vascular network within 
engineered tissues. We envision that OAPAO hydrogels could ultimately 
become a tool for the creation tissue-like structures to be used as 
improved in vitro models to enhance the efficacy of drug screening and 
clinical treatments. 
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1. Introduction 
Tissue engineering is an emerging field that addresses the current clinical 
need of human tissues replacements [1]. Tissue substitutes are generally 
required after a trauma or tumor resection, or as a result of other 
pathologies [2]. Current autologous treatments for soft tissue defects still 
present a number of challenges and limitations, such as donor-site 
morbidity and volume loss over time [3]. Therefore there is still a strong 
need for alternative strategies to repair soft tissue like fat, nerves, blood 
vessel and fibrous tissue. The field of tissue engineering aims to address 
this problem providing novel strategies based on the development of 
bioactive tissue constructs in vitro, that can replace the tissue in both 
structure and function, when implanted in vivo [2]. The development of in 
vitro human tissue would offer a major innovation in soft tissue 
reconstruction strategies [4].  
By serving as a temporary milieu for extracellular matrix (ECM) and 
providing the appropriate signals for growth and tissue formation, the 
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scaffold has become a fundamental element of tissue engineering 
processes [5,6]. Scaffolds for soft tissue engineering are typically 
designed to be highly porous with an interconnected open cell structure, 
to improve cellular infiltration and viability, to enable nutrients mass 
transport, to be structurally robust, and ideally, to promote angiogenesis 
and normal cell signaling processes [6-8].  
Besides the 3D structure, the ability of a scaffold to promote cell 
adhesion and proliferation, due to cell-substrate interaction, is a success 
prerequisite for soft tissue engineering scaffolds [9,10]. In fact, the 
natural extracellular matrix (ECM) provides, not only mechanical support 
and surface adhesion, but also regulate cell function. Cells communicate 
with the ECM via integrins; signaling pathways through integrins can alter 
gene expression and result in cell migration, differentiation, proliferation 
or apoptosis [11,12]. Previous studies showed that surface modification 
of biomaterials with cell-recognition sites can enhance interaction 
between cells and matrix materials [13] and human umbilical vein 
endothelial cells (HUVECs), as an angiogenesis model, do not exempt 
[14,15]. Furthermore, peptide-modified biomaterials not only condition 
cell-matrix interaction in vitro but also influence the in vivo 
microenvironment on the molecular level, which is critical for tissue 
reconstruction [16,17]. As reported by Yu and co-workers [18], an Arg-Gly-
Asp tripeptide (RGD) modified alginate can promote HUVECs viability and 
trigger new vessel formation. They suggest that integrin–ligand interaction 
may induce host tissue regeneration. 
Growing interest had been paid toward the design of three dimensional 
macro porous structures, starting from natural origin biomaterials, such 
as collagen and gelatine, containing RGD motifs, which are well 
recognized by RGD-dependent integrin cell receptors and plays an 
important role in cell adhesion and proliferation [19-23]. Unfortunately, 
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the application of natural polymers in clinics is still hampered due to 
undesirable immune response, deriving from their allogenic or xenogenic 
origin, and the presence of impurities and endotoxins, depending on 
large-scale isolation techniques [24]. Unlike natural origin polymers, 
synthetic polymers gather a series of advantages like: versatility, 
controlled degradability and adequate mechanical properties. However, 
they need expensive surface or chemical modification, commonly using 
RGD peptide, in order to improve their cell adhesion capacity [25-29]. In 
order to improve cell adhesion of some synthetic polymers, Tanahashi 
and co-workers [30] pioneered chemical modification exploiting the co-
polymerization with 4-(aminobutyl)guandine (Agmatine). They 
demonstrated that guanidine moieties are well recognized by RGD-
dependent receptors, such as integrine, due to its similar chemical 
structure to RGD-tripeptide. This revolutionary approach boosted the use 
of synthetic polymers in tissue engineering offering an alternative solution 
to promote cell adhesion, avoiding expensive modification with RGD 
tripeptide. 
Following the same approach, Ferruti and co-workers demonstrated that 
Agmatine-containing cross-linked poly(amido-amine)s (PAAs), show 
excellent capacity to promote cell adhesion and proliferation on its 
surface [31,32]. In a recent study carried out by our research group 
[33,34], we developed a wide library of Agmatine containing PAA based 
hydrogels, characterized by enhanced mechanical properties and 
degradation dynamics. Among these biomaterials, those obtained from 
free radical polymerization of diacrylamide-terminated poly(amido-amine)s 
oligomers (OPAA), containing RGD-mimetic repeating units, showed 
excellent capacity to promote Madin-Darby canine kidney (MDCK) 
epithelial cells adhesion on their surface.  
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In this work, we hypothesized that the excellent biological properties of 
Agmatine-containing PAA hydrogels could be exploited in tissue 
engineering, especially in soft tissue regeneration, when micro fabricated 
in a proper three-dimensional open-pore structure. We aimed to 
investigate how RGD-mimetic repeating units can orchestrate cell 
migration, proliferation and matrix deposition through macro porous 
constructs. A special attention was paid to evaluate the capacity of PAA 
open-pore foam (OPAAF), containing RGD-mimetic repeating units, to 
promote adipogenesis and in the stimulation of neovascularization in vitro 
and in vivo. In this work, we also investigated the effect of cross-linking 
density on chemical physics properties of PAA foams. To this aim, 
chemical physics and even biological characterizations were evaluated, 
starting from OPAA solutions, of two different concentrations: 25 and 
38% (w/w). Both of the polymeric precursor solutions were cross-linked by 
free radical polymerization and obtained as open-pore structures by 
foaming before reaching their gel-point.  
 
2. Materials and Methods 
 
2.1 Materials 
4-aminobutylguanidine sulfate (Agmatine), ammonium persulfate (APS), 
lithium hydroxide monohydrate (LiOH), hydrochloric acid (HCl), ammonium 
bicarbonate (NH4HCO3) and poly(ethylene glycol) sorbitan monolaurate 
(Tween®20) were purchased from Sigma-Aldrich at the highest degree of 
purity available and used as received. Milli-Q grade water was used in all 
the experiments. Phosphate buffered saline (PBS) IX contained 2.69 mM 
KCl, 136.89 mM NaCl, 3.21 mM Na2HPO4 and 1.47 mM KH2PO4. All 
solvents were purchased from Sigma-Aldrich and used without further 
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purifications. 2,2-Bis(acrylamide)acetic acid (BAC) was prepared as 
previously reported [35] and its purity (99.9%) determined by acid-base 
titration and by NMR spectroscopy. All biological materials were 
purchased from Sigma-Aldrich unless otherwise specified. 
 
2.2 Synthesis of diacrylamide-terminated poly(amido-amine)s oligomer 
OPAA: 
In a 50 mL round-bottom flask, equipped with magnetic stirrer and 
nitrogen inlet, BAC (9g, 44.9mmol) and LiOH (2.2g, 51.3mmol) were 
dissolved in 15mL Milli-Q water. Agmatine (7.6g, 32.2mmol) was then 
added to the reacting mixture under magnetic stirring. The reaction was 
kept in dark and proceeded under inert atmosphere at 35°C for one week 
and stopped by acidification till pH=4 using HCl 1M solution. The product 
was purified by Utra-filtration, using 1000 cut off semi permeable 
membrane. OPAA was obtained as fine white powder after freeze-drying 
using Telstar Cryodos 50 lyophilizer. The reaction Yield was 84%. Average 
molecular weights (SEC-Pullulane standards): Mn=2000, Mw= 2600, P.D. 
Index= 1,3. H NMR (D2O): 1.57 (s, 2H, -CH2-CH2-NH-CNHNH2); 1.70 (s, 
2H, -N-CH2-CH2-); 2.71 (s, 2H, -CH2-CONH); 3.07(s, 2H, -CH2-NH-CNHNH2); 
3.14 (t, 2H, -N-CH2-); 3.61 (m, 2H, -NH-CH2-(CH2)2-NHCO-); 5.48-5.68 (m, 
2H, CH2=CH-CONH-); 6.18(m, 1H, CH2=CH-CONH-) 
 
2.3 OPAA foams (OPAAF) preparation 
Foams were prepared by APS-initiated free radical polymerization of OPAA. 
Open cell foams have been obtained due thermal decomposition of 
NH4HCO3 at 60°C simultaneously to gelling reaction. Tween
®20 has been 
used as pore opening agent. Two open cell foams have been prepared 
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due to table 1. pH of the raw foams were adjusted to neutral, using 
0,01M solution of citric acid. Discs of 10mm diameter and 3mm height 
have been cut and soaked at room temperature in 50% (w/w) ethanol 
aqueous solution for 2 days, and washed in Milli-Q water on orbital 
shaker for other 3 days, then dried from ethanol under reduced pressure 
(0,01bar) and UV-sterilized prior to cell seeding. Schematic 
representation of OPAA crosslinking through free radical polymerization is 
reported in Fig. 1. 
  
2.4 Scanning electron microscopy 
SEM images have been acquired using Carl ZEISS-Sigma scanning 
electron microscope, endowed with EDS-Brucker XFlash 5030-127eV 
detector.  
 
2.5 Size Exclusion Chromatography 
Traces were recorded using Toso-Haas 486 columns, Waters 515 HPLC 
pump and UV detector operating at 230 nm. The mobile phase was 0.1 M 
Tris buffer saline, pH 8.00±0.05. The follow rate was 1ml/min. OPAAs 
average molecular weights were calculated using Pullulane standards. 
 
2.6 Nuclear magnetic resonance NMR 
1HNMR spectra were acquired on Bruker 8 Advance 400 spectrometer, 
operating at 400.133 MHz. 
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Figure 1. Schematic representation for OPAA foams syntheses 
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Table 1, composition of OPAA foams 
 
2.7 Mechanical characterization 
The mechanical properties of OPAA foams were studied with a dynamic 
mechanical analyzer (DMA mod. 2980, TA Instruments), using mechanical 
compression tests in frequency sweep and stress relaxation tests with 
subsequent strain recovery. All the mechanical tests were conducted on 
cylindrical specimens (ø = 5 mm, h = 3 mm) previously brought to a 
swelling plateau in distilled water. Six specimens were characterized for 
each formulation. Compression tests were performed in frequency sweep 
(f = 0,3, 1, 2, 3, 5 and 10Hz, n = 10 cycles) at a constant temperature 
(37°C) to obtain the complex modulus trend on variation of frequency. In 
particular, information can be obtained about the real component of the 
complex modulus, known as the conservative modulus (E’), which 
represents the energy accumulated in the material and consequently 
correlated with its elastic behavior, and the imaginary component, called 
the dissipative modulus (E”), which represents the dissipated energy 
linked to the viscous component of the material. The E”/E’ ratio, called 
Tanδ, allows the contribution made by the two components to be 
evaluated on variation of the test parameters.  
 
OPAAF 38OPAAF 25
g weight % g weight %
OPAA 1 24.7 1 37
Milli-Q water 1.5 37 0.67 25
Tween®20 0.05 1.3 0.08 2.88
APS (0,1mM) 0.5 12.3 0.3 11
NH4HCO3 1 24.7 0.65 24
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2.8 Equilibrium swelling and weight loss measurements 
Tests were carried out in PBS 1X, using dry cylindrical samples of average 
weight 70 mg ± 10mg. Samples incubated at 37 °C and weighed at time 
at fixed time intervals. At each time point, the swollen samples were 
removed from PBS, blotted gently to remove excess PBS. For weight loss 
measurements, samples were washed in Milli-Q water, to remove PBS 
from the swollen foams, finally freeze dried and weighted. Swelling 
capacity and weight loss were calculated according to the following 
formulas: 
Swelling degree % = (Ws-W0)*100/W0   (Equation 1) 
Weight loss %= (W0-Wd)*100/W0   (Equation 2) 
 
Where W0, Ws and Wd in equations 1 and 2 are the initial, swollen and 
dried weight respectively. 
 
2.9 Cell culture and seeding 
HUVECs were obtained from PromoCell Gmbh (Heidelberg, Germany). The 
cells were cultured in M199 medium (Sigma-Aldrich) supplemented with 
2mM L-Glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin 
and freshly added with 20% FBS (Sigma-Aldrich), 50 ng/ml β-endothelial 
cell growth factor (ECGF) and 100 µg/ml Heparin. HUVECs were 
harvested using 0.05% trypsin, centrifuged and resuspended in basal 
medium. Each scaffold, of 10mm diameter and 2mm thickness, was 
seeded with 1x106cells, resuspended in 100 µl of basal medium. 
Scaffolds were seeded adding drop-wise cells suspension, then were 
placed in the incubator for 1 h to allow cell attachment. Thereafter, 1mL 
of corresponding medium was added to each well, and the plates were 
incubated at 37°C in 5% CO2 95% air-humidified incubator. 
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2.10 Confocal microscopy 
Cellular viability was investigated at 3 and 7 days of culture by using a 
live/dead assay solution consisting of Calcein-AM (1 µM) and Propidium 
Iodide (0.1 mM) prepared in PBS. Briefly, samples were rinsed in PBS, 
immersed in staining solution for 15-20 minutes and incubated at 37°C. 
Staining solution was removed, samples washed twice with PBS and 
immersed in PBS before imaging. Live imaging was performed using a 
confocal microscope (Leica Confocal Microscopy TCS SP5) incubator 
equipped using 490/515nm (excitation/emission) for Calcein-AM (Life 
Technologies) and 535/617nm  (excitation/emission) for Propidium 
Iodide. Maximum intensity projection images were obtained using ImageJ 
software. Cell organization on scaffolds validated 3 times.  
 
2.11 In vivo biocompatibility 
Female CD1 mice (Charles River) aged 8 weeks (25-31 gr) were used for 
this study.  Under general anesthesia, a 10 mm-long incision was made 
in the skin of the medial femoral region. Scaffolds (3 for type and time 
point) were placed subcutaneously, over the femoral artery, between the 
inguinal ligament and hiatus adductorius, keeping the perfusion of the 
distal leg intact. The incision was closed with interrupted 6/0 single 
filament ethilon (Biomedica Greto) sutures. Mice were sacrificed 51 days 
post implant, and scaffolds together with surrounding tissues were 
excised, and fixed in 10% neutral buffered formalin. Formalin-fixed 
samples were embedded in paraffin wax, sectioned at 4µm thickness, 
routinely stained with hematoxylin and eosin (HE), and evaluated under a 
light microscope for the assessment of host reaction and tissue ingrowth.  
 
Chapter 4 
 
Page 77 !
3. Results and Discussion 
Foaming, compared to other common micro fabrication techniques such 
as solvent casting and particulate leaching, is the preferred choice for 
hydrogels obtained from free radical polymerization of water-soluble 
polymeric precursors. In fact it does not require the use of organic or 
toxic solvents, neither the complicated steps necessary for the 
elimination of porogen [28]. In this work, foaming of OPAA cross linked 
hydrogels took place thanks to the thermal decomposition of NH4HCO3, 
which release carbon dioxide and ammonia gas in the liquid polymeric 
solution, before and during cross-linking. Tween®20 were added to 
achieve homogenous pore size distribution and open cell structure. The 
average pore size, from 50 to 400 µm, is in the same range for both 
scaffold types, however, the pore structure of the OPAAF 25 scaffolds is 
characterized by higher interconnection, whereas the OPAAF 38 appear 
less interconnected with small and randomly distributed pores (Fig. 2).  
 
 
Figure 2. SEM images micrographs for OPAAF 25 (a) and OPAAF 38 (b) respectively (scale 
bar 200 µm) 
 
 
a b 
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Swelling kinetics of OPAA foams are graphically represented in Fig. 3. 
Both OPAAF 25 and OPAAF 38 reached the maximum swelling capacity 
“Plateau” in the first hour. Interestingly, OPAAF 25 swells twice than 
OPAAF 38. This difference reflects the effect of the cross-linking degree, 
the macromolecular mesh size and the foams architecture (pore structure 
and dimension). Degradation kinetics of OPAA based hydrogels, 
previously studied by Martello et al. 2013 [34], showed 25% weight loss 
during the first month of incubation, and proceeded gradually to reach 
60% within the sixth month of incubation in PBS at 37°C.  
 
 
Figure 3. Swelling kinetics of OPAA foams in PBS 1X at 37°C 
 
Mechanical characterization of OPAA foams (Fig. 4) shows remarkable 
relation between the elastic modulus E’ and OPAA concentration, in each 
formulation. The higher the OPAA concentration, the stiffer the foam. This 
characteristic is directly related to the difference in their cross linking 
density. We observed that E’ values were maintained invariable as 
frequency increased gradually from 0.3 to 10Hz (Fig. 4a).  
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Figure 4. (a) Compressive elastic modulus E’ (kPa) and (b) Tanδ, respectively, as functions 
of frequency (Hz). 
 
The imaginary dissipative energy, related to the viscous component was 
evaluated at different frequencies (Fig. 4b). Significant increase in Tanδ 
was observed for OPAAF 25 at higher frequencies. This could be 
attributed to material fatigue, probably due to the strain used for the 
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mechanical characterization. Interestingly, the viscous component was 
less evident for OPAAF 38. In general, the elastic behavior of OPAAFs 
make them a suitable candidate as scaffolds for soft tissue engineering, 
where elasticity and adequate mechanical support influence morphology, 
orientation of cultured cells and induce changes in signal transduction 
system and secondary messengers, especially for certain types of soft 
tissues, as for example adipose tissue [37-40]. 
To evaluate the biological properties of OPAA hydrogel foams containing 
RGD-mimetic repeating units, the cell-scaffold interactions (cell adhesion, 
distribution and viability) were extensively studied. HUVECs growth on 
OPAAF 25 and OPAAF 38 was visualized over time by confocal laser 
scanning microscopy (CLSM) after live/dead staining. After 7 days of 
culture, cells were covering the complete surface and growing into the 
scaffold pores (Fig. 5 and 6). Imaging revealed layers of viable cells 
(green) and some dead cells (red) that can be discerned among 
predominantly viable cells. Cells were regularly distributed on scaffolds of 
both types, with uninterrupted cell layers on the OPAAF 38 (Fig. 6b). 
OPAAF 25 also exhibited continuous cell layers, although HUVECs did not 
grow on all edges of the scaffold pores (Fig. 6a). Moreover, the shape of 
primary HUVECs was more rounding, short-spindle, on OPAAF 25, while it 
was more flat, long-spindle, on OPAAF 38.  
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Figure 5. Confocal microscope images, live/dead assay for HUVECs seeded in OPAAF 25 
(a) and OPAAF 38 (b) respectively, after 3 days of culture (scale bar, 100 µm). 
 
 
Figure 6. Confocal microscope images, live/dead assay for HUVECs seeded in OPAAF 25 
(a) and 38 (b) respectively, after 7 days of culture (scale bar, 100 µm). 
 
a 
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The assessment of in vivo biocompatibility of OPAA foams was performed 
in a mouse model with subcutaneous implant in the medial femoral 
region. All mice tolerated well the constructs and did not develop 
limitations in leg movement. Healing of incision site was achieved within 
3 days, and all implants were retained until the end of the experiments. 
As a first gross evaluation during removal, both constructs appeared well 
integrated at the implantation site, and newly formed tissue was evident 
within the pores. After paraffin-embedding and HE staining, scaffolds 
were microscopically analyzed (Fig. 7).  
 
 
Figure 7. Histological examination of OPAA scaffolds after 51 days of implantation.  A-E) 
OPAAF 25. F-L) OPAAF 38. Scaffolds were well integrated in the subcutaneous tissue, their 
overall porous structure was preserved, and infiltrating tissue filled the scaffold pores (A 
and F). Inflammation (*) was most prominent along the contact surface between the 
scaffold and underlying skeletal muscle (M) (B and G), multinucleated giant cells 
attempting to phagocytize the scaffold were found (arrows and insert). Infiltrating tissue 
was composed of vascularized adipose tissue (C and H), dense connective tissue 
(fibrosis) (D and I) and loose connective tissue (E and L). Arrowhead: femoral artery. 
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During sectioning, OPAAF 38 was difficult to cut given its stiffness, 
resulting in fragmentation of the scaffold in the histological sections. 
Both OPAA foams appeared dark-red to brown in HE stained sections. 
Both OPAAF 25 and OPAAF 38 had a homogenous structure containing 
unstained vacuoles, that were occasional and small-sized in OPAAF 25 
and more numerous and variably sized in OPAAF 38. After 51 days of 
implantation, both scaffold types were well integrated in the murine 
subcutaneous tissue and their overall structure remained intact. Fibrous 
encapsulation was mild and incomplete around both scaffolds. 
Inflammation was overall mild, localized at the periphery of the scaffold, 
and composed of small to moderate numbers of macrophages, and 
lesser numbers of granulocytes (both neutrophils and eosinophils), 
lymphocytes, and foreign body multinucleated giant cells, in an attempt to 
phagocytize the implanted material. Slightly stronger host reaction was 
observed along the surface in contact with underlying skeletal muscles, 
while surrounding adipose tissue appeared almost unaffected by the 
presence of the scaffolds. As regards the tissue ingrowth, the pores of 
both scaffolds were infiltrated by adipose tissue and vascularized fibrous 
tissue (denser at the periphery and looser towards the center of the 
scaffold), growing over the surface of the material and occupying the 
cavity of pores. In OPAAF 25 there was more fibrosis compared to OPAAF 
38. Overall, both scaffold types showed a good biocompatibility and 
tissue ingrowth, supporting their application in soft tissue engineering. 
 
4. Conclusion 
The increasing clinical demand for innovative therapeutic approaches able 
to improve patients’ quality of life drove the scientists’ attention toward 
regenerative medicine. This interest was catalyzed by its extraordinary 
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potential in volume and function compensation of damaged tissues, 
especially after trauma or tumor resection. Soft tissue engineering 
represents an important challenging field, where scaffolds morphology, 
biomechanics and cell-substrate interaction drastically influence the 
phenotype, signal transduction and cell differentiation of the regenerated 
tissue. The most studied biomaterials for soft tissue engineering are 
classified into natural origin and synthetic polymers. Problems related to 
natural origin polymers and expensive surface and chemical modifications 
of non-adhesive synthetic polymers motivated scientists to explore new 
functional classes of biomaterials, able to overcome drawbacks of the 
biomaterials cited above. Synthetic polymers containing RGD-mimetic 
repeating units, open new frontiers for the development of cell adhesive 
biomaterials in large scales. In this work we aimed at drawing the 
attention toward the potentials of synthetic RGD-mimetic poly(amido-
amine)s polymers in tissue engineering. 
Besides the excellent biological properties, RGD-mimetic PAA-based 
macro porous foams, are characterized by degradation kinetics and 
mechanical properties which match those required for soft tissue 
engineering scaffolds. The reported results have important implications 
for the design of scaffolds for soft, in particular adipose, tissue 
engineering. Successful adipose tissue engineering approaches rely on 
both adipose differentiation and the rapid recruitment of a vascular 
network to meet the metabolic requirements of the newly formed fat pad 
[41]. It may be possible to satisfy these biological design parameters by 
the development of scaffold composites controlling and guiding 
angiogenesis in vivo. Specifically, our results indicate that OPAAFs may 
be able to accelerate vascularization thanks to their ability to promote 
endothelial cell adhesion and proliferation in response to the elevated 
presence of RGD-mimetic sites. This process may be further enhanced, 
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because increased matrix rigidity promotes blood vessel formation by 
directly altering endothelial cell behavior [42]. This possible perturbation 
of blood vessels homeostasis represents an important issue, and better 
insight can help controlling and guiding angiogenesis and adipogenesis in 
a scenario where adipose tissue engineering is predominantly pursued for 
reconstruction therapies for breast cancer patients [43]. Future in vivo 
studies are required to specifically address these aspects. 
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1. Introduction 
The field of tissue engineering is dedicated to repair, restore or improve 
the functions of damaged or lost human tissues [1]. The aim of tissue 
engineering is to create functional tissues and organs in vitro and to use 
them as transplants or in vitro test systems [2]. Nevertheless, despite 
significant progresses have been achieved over the last 20 years, a 
number of challenges remain, preventing the widespread of tissue 
engineering clinical applications [3]. Perhaps the most important 
scientific issue hampering the development of tissue engineering 
technologies is the lack of a proper vascularization [4]. Nowadays only 
skin, cartilage and bladder grafts are successfully used in clinics [5–
10] while cornea grafts are far ahead [11,12], mainly thanks to their low 
requirement for nutrients and oxygen that can be met by the host's 
vascularization. However, only few tissues can be successfully supplied 
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via diffusion from blood vessel systems that are further away [13,14]. In 
particular, this approach fails when applied to complex and large tissues 
[15]. This is due to the fact that the formation of new blood vessels is 
indeed a slow phenomenon and the deficiency of oxygen and nutrients 
supply rapidly causes widespread cell death in graft cores [16]. This is 
true also for large tissue-engineered constructs that are supplied with 
oxygen and nutrients in vitro by using perfusion bioreactors but after 
implantation in vivo they are supplied by diffusion only [17]. In fact, in the 
body most tissues rely on a highly branched system of multiscale blood 
vessels [18,19]. Living cells are generally found no more than 200 µm 
from the nearest capillary [20,17]. This spacing allows optimal diffusion 
of oxygen, nutrients, and removing of metabolic waste products to 
support and maintain viable tissues [21,22]. Likewise, any tissues grown 
in the laboratory, that is more than a few hundreds of microns thick, 
needs a vascular system and when this condition is not satisfied, cells 
quickly become irreparably damaged [23]. Diffusion limitation is the 
primary reason why the construction of tissues thicker than a few 
hundred microns is currently not practicable in vitro [22]. Overcoming the 
current inability to engineered tissue with blood vessel architecture is 
critical to create large and complex in vitro tissues and to transfer tissue 
engineered constructs to the clinic [15,18,24]. 
It is known that scaffold itself should be able to promote vascularization 
[25]. To date, several methods have been developed to generate 
engineered scaffold with perfusable vascular network. One of these 
methods to construct capillary networks is layer-by-layer assembly [26-
29]. In brief open microfluidic channels are imprinted into one layer such 
that a second fabricated layer can then be aligned and bonded forming 
closed channels in an iterative manner. Layer-by-layer assembly requires 
a delicate and slow fabrication process of accurate stacking and 
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lamination of individual layers. It also imposes considerable design 
limitations on the materials and on the capillary architecture [30,31]. 
Bioprinting, is an alternative approach in which living as well as non-living 
materials with a precise 3D organization are patterned and assembled in 
a computer-aided printing processes [32]. Currently, this is a long 
process with strong limitations on resolution and printable materials [30].  
In contrast to the methods described above, sacrificial templating 
provides a more scalable solution to rapidly and precisely construct 
vascular networks [33-35,19]. Molded gelatin was used as a sacrificial 
element to create microfluidic networks within collagen, fibrin, and 
matrigel. Alternatively sacrificial sugar structures were used to form a 3D 
fluidic vascular network with diameters and densities similar to those of 
capillaries. In this case a rigid 3D lattice of melt-spun sugar filaments 
have been casted in a polymeric matrix, and then sacrificed to create 
microfluidic architecture in the bulk. In a similar approach, 3D printed 
rigid filament networks of sugar glass were also used to generate 
perfusable cylindrical networks in cell-laden gels [19].  
However, 3D sacrificial molding has so far been limited to specific casting 
material and to a narrow range of crosslinking and polymerization 
strategies. In this paper, we used a biocompatible sacrificial material, 
and a means to mold it, in the casting of branched 3D vascular networks 
for large engineered tissues. The polymer utilized in the fabrication of the 
sacrificial template is poly(vinyl alcohol) (PVA). PVA is a water-soluble 
synthetic thermoplastic polymer with sufficient rigidity [36] to support the 
weight of an open branched 3D microfluidic network and the ability to 
rapidly dissolve compatibly with living cellular environment [37]. The 
thermoplastic nature of PVA makes this material an ideal candidate for 
industrial production [38]. PVA is already suitable for the most common 
industrial fabrication technologies (e.g. injection and compression 
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molding) [38] and 3D printing [39]. This flexibility results in a great 
advantage in terms of process scalability and costs compared to the 
other sacrificial materials. We demonstrated that 3D molding based on 
PVA sacrificial structures is compatible with synthetic and natural 
biomaterials and with a wide variety of different crosslinking and 
polymerization strategies. In this work first we have generated branched 
microfluidic networks in biocompatible matrices and demonstrated that 
these networks are able to sustain the cell viability of murine embryonic 
fibroblast in the core of cell-laden constructs. Second we have seeded 
those microfluidic networks with primary endothelial cells and we have 
perfused them into a custom made bioreactor to form a one-layer tubular 
endothelium hierarchically branched as a vascular network. 
 
2. Materials and Methods 
All starting materials were purchased from Sigma Aldrich and used as 
supplied unless otherwise stated. 
 
2.1 Fabrication of Plexiglas mold 
Two different microfluidic patterns were designed and converted into 
STEP files using AutoCAD mechanical 2012. Both patterns were copied 
on a 10 mm Plexiglas sheet using a computer numerical control machine 
(Mikron HSM 600) with the aid of open-mind hyperMILL cad/cam 
software, producing an open microfluidic negative mold (Fig. 1b).  
 
2.2 Casting of sacrificial templates 
The mold was treated with a solution of castor oil and ethanol (15% w/w) 
to make it hydrophobic and non-adherent to the PVA solution. 
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Compressed air blowing was used to remove the excess hydrophobic 
solution. Then approximately 3 mm layer of aqueous PVA (Mowiol 4-88) 
solution (20% w/w) was casted on the mold and allowed to dry overnight 
(Fig. 1a). The dried PVA layer was leveled with a Teflon blade repeatedly 
wiped on the mold wetted with water. This iterative process efficiently 
removes the polymer excess out of the microfluidic track. The mold was 
then allowed to dry overnight and the sacrificial template was gently 
removed from the mold with tweezers (Fig. 2c). Some of the sacrificial 
templates were immersed in a 2% (w/w) solution of Poly(DL-lactide-co-
glycolide) (PDLGA, 50:50 lactide/glycolide ratio) in chloroform, similarly 
as described in literature [19]. All PVA templates were stored at 20°C 
with calcium chloride until use to avoid the absorption of ambient 
moisture. 
 
2.3 Glass slide silanization and mold fabrication 
Glass slides were silanized to be used in the molds fabrication. In brief, 
glass slides were washed with acetone, activated by plasma oxygen (70 
W, 70 s) and immersed in a trichlorododecylsilane (TCS) solution (5% v/v 
in petroleum ether) for 10 minutes. Afterwards, glass slides were washed 
in succession with petroleum ether and ethanol, dried with gentle air flow 
and stored at room temperature. The mold for microfluidic experiment 
was prepared using two preformed silicone spacers of 1 mm thickness, 
with a rectangular void area of 20X12 mm interposed between two 
silanized glass slides. The PVA sacrificial structure was placed in mold 
and pressed between the two silicone spacers. In this way, the sacrificial 
structure is suspended in the middle of the rectangular chamber 
(20X12X2 mm) created by the void parts of the silicone spacers. In case 
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of multilayer mold, multiple sacrificial structures were suspended in the 
mold simply by adding silicone spacers.  
The mold for cellular experiments was fabricated in a similar manner, by 
using two custom-made PDMS silicone spacers of 1 cm thickness. Each 
one has a semicylindrical void area of 5 mm radius and 15 mm height. 
The sacrificial structure was placed and fixed between the two PDMS 
spacers and suspended in the middle of the cylindrical chamber created 
by the void parts of the PDMS spacers. 
 
2.4 Fabrication of microfluidic hydrogels 
To form a microfluidic gel, the liquid gel precursors, were injected into the 
mold, described in section 2.3, around the sacrificial template and 
solidified, making sure that the sacrificial structure remains completely 
immersed except for its ends (Fig. 3). Gel precursors used in the 
fabrication of microfluidic gels were hydroxyethyl methacrylate (HEMA), 
agarose and gelatin methacrylated (GelMA). Gels were prepared following 
the procedures described in detail in the sections 2.7, 2.8 and 2.9. 
Gelation was achieved in different ways depending on the specific 
precursor. HEMA gelation in poly(hydroxyethyl methacrylate) (PHEMA) was 
achieved by free radical polymerization initiated by APS/TEMED. GelMa 
hydrogels were obtained by exposing the pre-polymer solutions to a long 
wavelength UV lamp (B-100AP, UVP LLC, 365 nm, 10 mW/cm2) for 5 
min. Agarose gel was let solidify at 4°C for 20 min. After gelation of the 
precursor, the sacrificial structure was removed by flushing with 
phosphate buffered saline (PBS) at 37°C. This procedure yields a 
microfluidic gel, with one hole at each end. Multilayered lattice were 
successfully fabricated in a similar manner by stacking different sacrificial 
structure separated by 1 mm (Fig. 4) For microfluidic study, the 
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gels were perfused with 5-10% w/v aqueous solution of dyes (E122, 
E104, E131 and E142) and 0.5 µm fluorescent microspheres (Latex 
beads fluorescent red), using a micro pump (Mp-6 micropump, Bartels), 
connected to the gels trough silicon tubing (perfusion rate 0.6 mL/min) 
(Fig. 5,6). 
 
2.5 Fabrication of microfluidic porous hydrogels. 
Two different methods were used to prepare porous hydrogels, namely 
foaming and salt leaching. According to the first method, the polymeric 
precursor solution was prepared by mixing HEMA (35% w/w), 
poly(oxyethylene) (20) sorbitan monolaurate (Tween 20, 3% w/w), 
tetrametiletilendiamine (TEMED, 4% w/w) and ethylene glycol 
dimethacrylate (EGDMA, 2% w/w), as a crosslinking agent, in a mixture of 
ethylene glycol and water (1/3 w/w). According to the second method, 1 
g of NaCl salt crystals were crushed using a mortar and a pestle, and 
then added to a 2 mL salt saturated polymeric precursor solution 
containing HEMA, TEMED and EGDMA with the same proportions 
described in the first method. Then, to induce the free radical 
polymerization, 21 µL of aqueous ammonium persulfate (APS) solution 
(20% w/w) was added to the hydrogel pre-polymer solution to start a free 
radical polymerization. The foaming solution was rapidly injected into a 
large cylindrical mold, similar to the one described in section 2.3, and 
vigorously shaken until stable foam is obtained. Unlike the previous the 
salt leaching precursors paste was manually placed in each mold halves 
and then compressed around the sacrificial template by closing the mold. 
After gelation the microfluidic porous gels were purified from solvent, 
unreacted monomers and porogen, together with sacrificial structure 
removal, by washing at 37°C with ethanol/water a solution (50% w/w) 
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under mechanical stirring. Washing cycles were performed every 8 hours 
for 3 days. Microfluidic porous gels were then washed in bi-distilled water 
for other 3 days using the same procedure. 
 
2.6 Cell maintenance 
NIH-3T3 murine embryonic fibroblasts (CRL-1658, ATCC, Manassas, USA) 
were kept at 37ºC in 5% CO2 95% air-humidified incubator. The cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented 
with 10% Fetal Bovine Serum (FBS), 2 mM L-Glutamine, 100 units/mL 
penicillin and 100 µg/mL–streptomycin. Once 80% confluent, the 25 cm2 
flasks were passaged (subculture ratio 1:4 for multiple flasks) every 2-3 
days. Human umbilical vein endothelial cells (HUVECs) were obtained 
from PromoCell (Heidelberg, Germany). The cells were cultured in M199 
medium supplemented with 2 mM L-Glutamine, 100 units/mL penicillin 
and 100 µg/mL streptomycin and freshly added with 20% of fetal bovine 
serum (FBS), 50 ng/mL β-endothelial cell growth factor (ECGF) and 100 
µg/mL Heparin. During perfusion experiments in bioreactor, cells were 
perfused with endothelial cell growth media EBM-2 (Lonza) supplemented 
with EGM-2 singleQuot Kit Supplemets and Growth (Lonza), and they were 
used through passage 8. 
 
2.7 Preparation of HEMA solution for microfluidic studies. 
Ethylene glycol solutions containing 50% (w/w) of HEMA and 0.5% (w/w) 
EGDMA, as a crosslinking agent, were prepared. Irgacure 2959 (Ciba, 
1000 mg/mL in dimethyl sulfoxide) was added to the hydrogel pre-
polymer solution to yield final concentrations of 2% (w/w). After the 
gelation, the microfluidic gels were further purified from solvent or 
Chapter 5 
 
Page 97 !
unreacted monomers of reaction by washing at 37°C with ethanol/water 
a solution (50% w/w) under mechanical stirring. Washing cycles were 
performed every 8 hours for 3 days. Microfluidic porous gels were then 
washed in bi-distilled water for other 3 days using the same procedure. 
 
2.8 Preparation of Agarose pre-polymer solution for cell viability studies. 
Low-melting point agarose was dissolved in sterile PBS (pH 7.4) to yield a 
final concentration of 2.5% (w/v) and heated to 70°C. NIH 3T3 fibroblasts 
were trypsinized, counted and suspended within the agarose solution at 
10 x 106 cells/mL that was cooled to ~42ºC and pipetted to ensure even 
cell distribution. Agarose solution was replica molded to yield a 
microfluidic hydrogel as described in Section 2.4. Cylindrical cell laden 
hydrogel constructs, 10 mm in diameter and 15 mm in height, were 
placed in cell culture flask containing 10 mL of DMEM and used as static 
controls. Encapsulated cells were also cultured for 3 days in bioreactor 
under perfusion at a rate of 0.6 mL/min.  
 
2.9 Preparation of GelMA hydrogel for endothelialized network formation. 
Methacrylated gelatin (GelMa) was synthesized as described previously 
[40]. Briefly, type A porcine skin gelatin was solubilized at 10% (w/v) into 
Dulbecco’s phosphate buffered saline (DPBS; GIBCO) at 60 °C. 
Methacrylic anhydride (MA) was added to the gelatin solution at a rate of 
0.5 mL/min under stirring at 50 °C until the concentration of MA was up 
to 20% v/v. The MA was reached and allowed to react for 1 h then 
additional warm (40 °C) DPBS was added to stop the reaction. The 
mixture was dialyzed against distilled water using 12-14 kDa cutoff 
dialysis tubing for 1 week at 40 °C to remove salts and methacrylic acid. 
After lyophilization for 1 week, a white porous foam was obtained and 
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stored at -80 °C until further use. Freeze dried GelMA was dissolved in 
ethylene glycol at 60 °C, containing the photoinitiator (Irgacure 2959, 
1000 mg/mL in dimethyl sulfoxide, 2% (w/w)), to yield a final 
concentration of 12% (w/v). GelMA pre-polymer solution was molded to 
yield a microfluidic hydrogel as described in Section 2.4. Microfluidic 
hydrogels were purified from solvent and exceeding initiator by washing 
with ethanol/PBS mixture (50% w/w, 40 mL) and then pure PBS. Washing 
cycles were performed every 8 hours for 6 days under mechanical stirring. 
The sacrificial structure was removed during washing. HUVECs were 
seeded in the vascular lumen by injecting the cells suspension (5x106 
cells/mL) into the vascular architecture with a micropipette. Microfluidic 
hydrogels were then immersed in fresh medium where HUVECs were 
allowed to attach in static culture for 3 hour before introducing flow. 
Cylindrical hydrogel constructs were perfused at flow rates of 1.5 
mL/hour in the bioreactor. Medium was replaced every 5 days. 
 
2.10 Cell viability and vascular network imaging. 
Murine fibroblasts viability was assessed by live/dead fluorescence 
assay (Calcein AM/Propidium Iodide, Life Technology). To this aim, 1 mm 
slices of microfluidic cell-laden hydrogel were imaged using a confocal 
microscope (Leica Microsystems, Leica SP5). Cross-section image 
montages of cell-laden hydrogels were composed using ImageJ. Similarly, 
HUVEC cells were visualized by applying a live/dead fluorescence assay 
to the microfluidic gel. Images were captured along the channel length by 
confocal microscopy. The autofluorescence background outside the 
microfluidic channels was removed using Adobe Photoshop. 
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2.11 Immunofluorescent staining of nuclei and the actin cytoskeleton 
After 7 days in culture, cells were fixed in situ with 4% paraformaldehyde, 
rinsed with PBS, permeabilized with 0.1% Triton X-100, blocked with 2% 
BSA and then incubated with Alexa fluor 555 directly conjugated to 
phalloidin, 0,11uM, (Invitrogen, USA) for 40 min at room temperature for 
filamentous actin staining. After washing in PBS, cells were stained with 
9.4µM of bisBenzimide H 33258 (Hoechst). Images were captured along 
the channel length and channel depth using a Leica SP5 confocal 
microscope. The autofluorescence background outside the microfluidic 
channels was removed using Adobe Photoshop. 
 
2.12 Numerical analysis of the shear stress 
In order to disclose appropriate microfluidic working conditions for 
vascular tissue-engineering experiments, a fluid-dynamic simulation was 
performed. A finite element model was built by using COMSOL 
Multiphysics platform (Comsol, USA). A three-dimensional model was 
developed to evaluate the shear stress inside the adopted microfluidic 
geometry. The mesh refinement was compliant with the achievement of 
reliable values of the observables, mainly shear stress and local flow rate. 
In particular higher number of elements is utilized in critical regions such 
as branches’ bifurcation. The resulting mesh consists of 234401 
tetrahedral elements. The wall of the calculation domain is set to be no-
slip. It thereby causes a pressure drop from the inlet to outlet, while the 
fluid pressure at outlet is fixed as zero. The considered working fluid is 
water assumed incompressible and with uniform and constant physical 
properties. The used dynamic viscosity, at the working temperature of 
37 °C, is according with the value reported in literature [41]. The inlet 
flow rate is the controllable input and its value is selected in order to 
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maintain the flow in the laminar regime. The mesh, the boundary 
conditions and the values of the input parameters are given in Table I. 
 
2.13 Bioreactor  
A modified version of U-Tube bioreactor [42] was designed for the 
perfusion of the microfluidic scaffold (Fig 1a). The bioreactor consists of 
three parts: the input reservoir, the scaffold chamber and the output 
reservoir. In particular, the scaffold chamber is designed in two parts: one 
open part housing the scaffold and the other used to press fit the 
scaffold (Fig 1b). These parts were fabricated by insertion of silicon pipe 
with crescent diameter and connected to the reservoir unit thanks to 
tube-to-tube connectors (Value Plastic, USA), and silicon tubing (VWR). 
Each 15 mL reservoir unit was made by one silicon tube with two tubing 
connector (Brand, Germany) at the extremities connected on the top to a 
syringe filter and at the bottom to T-valve. This configuration has the 
advantage to be adaptable to any scaffold size using silicon tubing with 
different diameters. This ability is crucial when dealing with soft hydrogel 
constructs. Moreover the bioreactor can be reused several times since 
every part is autoclavable. Once the input reservoir is filled with 15 mL of 
medium and the seeded scaffold is press-fit into the open chamber, with 
the help of the other part of the chamber, the bioreactor is ready to 
operate. The bioreactor was suspended vertically in the incubator to avoid 
cells from settling on the surface of the reservoir (Fig 1c). Flow of medium 
was induced and regulated with the use of a syringe pump (KDS 230 
Multi syringe Infusion/Withdrawal) connected to the input reservoir by 
silicon tubing. After the initial perfusion of 10 mL, the flow was reversed 
continuously every 6 mL.  
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TABLE 1. Fluid properties and modeling set-up used in simulation. 
 
 
Figure 1. (a) Perfusion bioreactor scheme. The cellular medium oscillates between the two 
reservoir columns, flowing through the sample chamber, housing the scaffold. The 
direction of flow is reversed every 6 mL achieving continuous perfusion. (b) The chamber 
is made of one open part housing the scaffold and one used to press fit the scaffold. (c) 
Image showing the actual system during a perfusion experiment in standard incubator. 
 
 
Theoretical basis Fluid flow mechanics Navier-Stocks equations
Density 1000 [kg/m3]
Dynamic Viscosity 6.9*10-4  [Pas]
Compressibility Incompressible flow
Temperature 310.15 [K]
Inflow rate 1.5 [ml/hour]
Type of fluid flow Laminar flow
Boundary condition (outlet) No pressure
Boundary condition (wall) No slip
Type of mesh element Tetrahedral
Maximum mesh size 64.9 [µm]
Minimum mesh size 7.0 [µm]
Fluid parameters
Environmental 
boundary conditions
Meshing
a c b 
Scaffold 
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3. Result and discussion 
 
3.1 Formation of sacrificial structures 
Sacrificial templates were prepared by casting process according to two 
different patterns (Fig. 2c). The first one was designed to mimic branching 
capillaries and their fluidic features for cellular studies (right side of Fig. 
2c). The second pattern was inspired to the work of King et al. [43] and 
intended for demonstrative purpose. Both the patterns were imprinted on 
plexiglas supports, to achieve negative molds. We demonstrate that the 
proportions of the sacrificial networks precisely replicate those of 
features on the casting mold (Fig 2b). In particular PVA meshes were 
characterized by a maximum features size of 500 µm and minimum 
dimension of 100 µm (Fig. 2c). Results show that our casting process 
allowed the generation of sacrificial template with predefined, multiscale, 
and reproducible patterns.  
 
Figure 2. (a) Schematic diagram of sacrificial template fabrication. Aqueous PVA solution 
is casted on the mold and allowed to dry. Polymer excess out of the microfluidic track is 
removed by etching so that the sacrificial template can be demolded. (b) Images of 
Plexiglas mold (scale bars, 1 mm). (c) Top view of PVA sacrificial templates (scale bars, 1 
mm). 
Drying Etching 
Mold 
Polymer Solution  
Template 
a 
b c 
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PVA was chosen as sacrificial material because of its solubility in water 
as well as its mechanical properties. Indeed, PVA is a stiff and elastic at 
25 °C, with Young’s modulus 41.3 MPa, fracture strain of 41.3 MPa and 
maximum strain of 111% [36]. Furthermore the optical transparency [44] 
of the PVA solution allowed homogeneous photopolymerization of 
hydrogel precursors and do not affect after dissolution live imaging. 
 
3.2 Fabrication of microfluidic gels 
 
To fabricate hydrogel with interconnected microvascular networks, 
sacrificial elements were soaked in the precursor mixture except at their 
ends. Since the two ends of the template were not enclosed in the gel, 
they melted yielding openings at its extremities; flushing with aqueous 
solution through these openings rapidly removed the template. The 
process yields a monolithic gel with a vascular network matching the 
pattern of the sacrificial elements and therefore the features impressed 
on the original mold. Fig. 3b and 3c show examples of a microfluidic 
PHEMA gel that contained 200 µm wide channels. SEM cross-section 
images showed that the orthogonal profile of channel walls was 
preserved (Fig. 3d and 3e). In fact, the casting procedure used to create 
the sacrificial template stamp generates features with rectangular cross-
sectional shapes. As expected, co-encapsulation and dissolution of three 
sacrificial templates produced microfluidic gels that contained three 
independent networks, as showed in Fig. 4d and 4e. It is worthy to note 
that channels were found to be smaller than the original features of the 
sacrificial template, which is probably due to sample shrinkage upon 
sample processing. Images of monolithic microfluidic gels confirmed that 
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the applied method is compatible with a wide range of materials (collagen 
and agarose), different precursors (i.e. HEMA and GelMA), different 
solvents (water, ethylene glycol and ethanol) and different crosslinking 
strategies (UV and free radical polymerization). The versatility of this 
approach is mainly due to properties of PVA. It is soluble in water, slightly 
soluble in ethanol, but insoluble in other organic solvents. Indeed, the 
PVA dissolution in dense aqueous media is slow enough to allow the 
matrix to be completely crosslinked before dissolution. PVA templates 
have shown to be compatible with either high and low molecular weight 
precursors thanks to its small pore size that prevents monomers from 
diffusing into the template during polymerization. When monomer 
diffusion occurs, as in the case of gelatin, the sacrificial structure 
becomes interpenetrated with hydrogel polymeric chain, thus occluding 
the microfluidic channels (data not shown). 
 
 
Figure 3. (a) Schematic fabrication diagram of microfluidic gels. (b,c) Optical images of 
microfluidic PHEMA hydrogels. Channels are slightly wider than the original template, due 
to the swelling of the hydrogels upon removal (scale bars, 1 mm). (d,e) SEM micrographs 
of multilayer microfluidic gel cross section (scale bar, 200 µm).!!!
Sacrificial 
Template 
a
Channel 
Network 
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e 
d 
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Figure 4. (a) Schematic diagram of fabrication of multilayers microfluidic gels. (b,c) Optical 
images of a multilayer microfluidic PHEMA gels (scale bars, 1 mm). (d,e) SEM micrograph 
of multilayer microfluidic gel cross sections (scale bar, 400 µm). 
 
 
Figure 5. (a) Schematic diagram of fabrication process of microfluidic porous hydrogels. 
The sacrificial structure is encapsulated into the liquid hydrogel precursor together with a 
porogen material. After crosslinking the sacrificial template and porogen are removed by 
washing with water, yielding an open perfusable channel network in a porous matrix. (b) 
SEM micrograph showing the cross-section of porous scaffold produced by foaming with 
embedded microfluidic channels (scale bars, 500 µm). (c,d) SEM micrograph 
magnification showing the cross-sections of two porous scaffolds produced by foaming (c) 
and salt leaching (d). Cross sectional images show that the channels can be connected to 
(c) or isolated (d) from the hierarchical porosity of the scaffold, varying the reaction 
conditions (scale bars, 200 and 100 µm). 
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3.3 Fabrication of microfluidic porous scaffold 
In order to demonstrate the integration between 3D sacrificial molding 
method and porous biomaterials we combined our method either with 
foaming or salt leaching techniques, that are commonly used to generate 
hierarchical porosity of tissue engineering scaffold. In brief the sacrificial 
structure was encased into the precursors mixture together with either a 
foaming solution or a porogen material. After the hydrogel crosslinking, 
both the sacrificial and the porogen elements were removed, leaving 
behind an interconnected microfluidic network within the porous matrix 
(Fig. 5a). The SEM images show the cross-sections of porous scaffolds 
with embedded microfluidic channels (Fig. 5b). We demonstrated the 
ability to generate microfluidic matrixes in which the fluidic pathways are 
connected (Fig. 5c) to or isolated (Fig. 5d) from the hierarchical porosity 
of the scaffold on both the porogen agent and monomer mixture. This 
results were possible thanks to the chemical and mechanical stability of 
the PVA sacrificial element. In fact, due to the low stiffness and thermal 
stability of the sacrificial material used so far, the sacrificial molding was 
not compatible with exothermic polymerization reaction [26], like those 
commonly used to generate porous matrices by foaming. 
 
3.4 Microfluidic Study 
To study the fluidic behavior of the gels, we placed a liquid solution at 
one extremity of the microfluidic network. This resulted in a convective 
flow of the solution through the channels, as shown by the delivery of 
500 nm diameter fluorescent microspheres (Fig. 6 a,c). The mechanical 
resistance of the microfluidic network was assessed by perfusing them 
with an aqueous suspension of fluorescent microspheres at a rate of 0.6 
mL/min. For these tests, microfluidic gel was connected to a micropump, 
as described in section 2.4. Under these conditions, we did not observed 
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any fracturing or deformation of fluidic features. This behavior can be 
ascribed to the monolithic nature of the gels as well as the lack of 
architectural seams, which make them suitable for non-leaking perfusion 
with laminar and turbulent flow. To establish whether microfluidic 
pathways increase the mass transport rate within the gels, we perfused 
them with a solution of azorubine at a rate of 0.6 mL/min (Fig. 6 b,d), 
and compared the diffusion of dye with that in bulk gels. Similarly, 
multilayer microfluidic gels were perfused using different dyes (Fig. 7 b,d). 
As expected, we noticed that the mass transport in a gel was enhanced 
by the presence of microfluidic networks and the PVA dissolution allows 
diffusive and connective transport into the bulk gel.  
 
 
Figure 6. a). Optical images and enlargements of single layer microfluidic gel perfused 
with red dye solution (a,b) and fluorescent microspheres (b,d) (scale bars, 1 mm and 400 
µm). 
  
a 
b 
c 
d 
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Figure 7. Optical images and enlargements representing a multilayers microfluidic 
networks in PHEMA gel perfused by different dye solutions (scale bars, 1 mm and 500 
µm). 
 
3.5 Cell viability study. 
Cell-laden engineered constructs can develop a necrotic core due to lack 
of adequate mass transport. Therefore a major requirement of an 
engineered vasculature is to sustain cellular activity for extended time at 
physiological cell densities [19]. With the aim to demonstrate that our 
fabrication approach allow a greater nutrient mass transfer we generated 
a perfusable cylindrical cell-laden construct with a single layer of fluidic 
channels within its center, as described in the section 2.8. In this case 
the sacrificial structure was coated with PDLGA before casting in order to 
avoid the deformation of the sacrificial template during the slow agarose 
solidification. The coating is then gently removed with a tweezer to avoid 
reduction of nutrients transport into the hydrogel. In static conditions, 
live/dead fluorescence assay showed that the inner sections of cell-laden 
hydrogel follow a trend of decreasing cell viability that became 
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pronounced after 72 hours of static culture (Fig 8). Noteworthy, viability 
was higher in perfused microfluidic hydrogel than in static control, as 
previously demonstrated [45]. In particular, high cellular survival was 
evident at the gel perimeter and near perfused channels. The cell viability 
decayed radially from the perfused channels, as shown in Fig. 8a. These 
data can be explained by considering that perfused channels provide the 
gel with a continuous renewal of nutrient and removal of waste products 
that otherwise accumulate in static systems. Accordingly, microfluidic 
networks were found to sustain 3D cell culture with higher viability and 
greater proliferation compared to cells grown in bulk hydrogels. These 
results demonstrate that patterned perfusable architectures are able to 
provide effective mass transport throughout dense cell-laden construct, 
which is a fundamental requirement for the transition of implanted 
engineered tissues in the clinical practice. 
 
 
Figure 8. Cross-section images montages of cell laden agarose gels with (a) and 
without fluidic channels (b). NIH 3T3 murine fibroblasts (107 cells/mL) 
embedded in the gels were stained, after 72h of culture, with a fluorescent 
live/dead assay (green, Calcein; red, Propidium iodide). Cells survive at the gel 
perimeter and near perfused channels, and survival decayed radially deeper in 
the gels (scale bar, 1 mm).  
a 
b 
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3.6 Endothelialized network formation. 
Endothelial cells were seeded as a dense suspension through one inlet 
of the microfluidic gel and quickly lined the walls of the entire branched 
vascular network. After perfusion for two days, cells still remain attached 
to the inner surfaces of the channels (Fig. 9a). 
 
Figure 9. (a) Optical images of branched GelMA microfluidic network seeded with 
HUVEC cells after 7 days of perfusion in bioreactor (scale bars, 1 mm and 500 
µm). (b) Live/dead fluorescent images showing different portions GelMA network 
coated on the walls by HUVECs (scale bars, 500 µm, 250 µm and 100 µm). 
 
After 7 days, HUVECs formed confluent monolayers that conformed to the 
channel walls (Fig. 9 and 10) and thereby formed square endothelial 
lining, as confirmed by optical and immunofluorescence cross-sectional 
images (Fig. 10). HUVECs deformed the features of the microfluidics 
networks, so that the angles of squared section became noticeably 
rounded, as previously shown [26,46]. The cell-induced deformation 
leaves open the microfluidic networks and doesn’t inhibit a continuous 
a 
b 
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perfusion of culture media. Both light microscopy and 
immunofluorescence imaging showed that most of the cells were aligned 
with the direction of the flow, as previously demonstrated [46]. 
 
 
Figure 10. (a,b,c) Maximum intensity projection confocal images of HUVEC cells grown in 
microfluidic channels of GELMA hydrogel. The cytoskeleton actin and nuclei were stained 
with phalloidin (red), hoechst (blue), respectively. Cells form confluent monolayers on all 
channel walls in single (a) and branched channel (b). Fluorescent (c) and optical (d) cross-
sectional images of three-dimensional reconstructions showing that HUVECs conform to 
the inner channel surfaces (scale bars, 100 µm for a,b and 50 µm for c,d).  
 
d 
Nuclei!
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c 
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Moreover, the organization of F-actin filaments was observed to change in 
response to shear stress. Depending on scaffold conditioning endothelial 
cells behavior and their angiogenic potential are altered, see Baiguera 
and Bagatti for a review [47], within this technique many factors and their 
combinations can be further studied. The formation of a confluent 
endothelial lining, regulating mass-transport exchange and controlling 
blood flow and vessel tone, is a fundamental requirement for vascularized 
living tissue. 
 
3.7 Shear stress analysis. 
Figure 11 shows the fluid flow velocity field as resulting from the 
simulation. The maximum locates inside the smallest branches of the 
microchannels. With a inlet flow rate of 1.5 (mL/h) the maximum flow 
velocity was calculated to be 6.005 (mm/s) and the corresponding 
Reynolds number 0.156. The latter value indicates that the flow regime is 
laminar, thus feed-backing the initial assumption on the fluid motion. 
Figure 12 shows the shear stress distribution. At the flow rates of 1.5 
mL/h the estimated maximum shear stress was 0.988 dyne/cm2 and 
localized at the channel walls. This value is comparable to those naturally 
sensed by vascular cells within the physiological conditions, which are in 
the range of 1–10 dyne/cm2 [50,51]. From the computational simulation 
suitable experimental conditions for vascular tissue engineering are then 
established. 
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Figure 11. Fluid flow velocity field (a) and surface shear stress profile (b) of the internal 
walls of microfluidic gel perfused at 1.5 mL/hour rate (scale bar, 1 mm). 
  
4. Conclusions 
We have demonstrated a novel sacrificial templating approach by 
constructing robust, multilayer, microfluidic networks in hydrogel and 
shown that they can be reliably perfused without leaks or occlusions.  
The obtained microfluidic networks have shown to provide effective 
nutrient and oxygen distribution throughout the hydrogel scaffold, 
resulting in cells with higher viability and greater proliferation as 
compared to cells grown in bulk gels. We also showed that PVA sacrificial 
molding is well suited for the creation of densely populated vital tissue 
a 
b 
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constructs with perfusable branching vascular channels. A key advantage 
of our method is that the perfusable scaffold is formed in a one step 
process simply by filling the empty volume around the template and by 
crosslinking the matrix. In fact it rapidity prevents the formation of a 
necrotic core in thick engineered construct. We expect that our method 
for controlled architecture of patterned fluidic networks coupled with 
further improvements in bioreactor technologies may enable the scaling 
of dense cellular constructs to large volume. Moreover, compared to 
other methods, it represents a progress in manufacturability and 
scalability, since it is compatible with a wide variety of synthetic and 
natural biomaterials, crosslinking strategies and polymerization reaction. 
The thermoplastic nature of the sacrificial element allows the use 
industrial processes (e.g. injection and compression molding) to 
manufacture it. This characteristic will allow rapid and reproducible mass 
production of multiscale microvascular architectures. Moreover, the 
chemical stability of sacrificial template guarantees a long-term storage 
and easy product distribution. We forecast that these characteristics will 
facilitate the adoption of the technology and its integration in many 
advanced therapies medicinal products.  
However this approach is still limited to planar networks or their stacks, 
lacking the three-dimensional versatility of photolithographic methods, 
such as stereolithography. In order to overcome this limitation, a possible 
solution is the integration of 3D printing technology in the fabrication of 
the sacrificial template. This will allow to rapidly and reproducibly 
generate microvascular architectures voxel by voxel. We expect that this 
will require a limited effort considering that PVA is already used in 3D 
printing as support material [39]. Preliminary experiments are ongoing to 
test the feasibility of this approach.  
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In this PhD thesis we have developed a technology platform towards the 
design of vascularizable scaffolds for large tissues engineering.  
To this aim we have designed a series of biodegradable and biomimetic 
poly(amidoamine) based hydrogels. In order to improve the mechanical 
and degradation properties of this class of materials, we investigated 
several key parameters of the synthesis reaction, such as monomer ratio, 
reaction time and introduction of acrylic chains. This approach allowed to 
achieve a variety of hydrogels and eventually resulted in the optimization 
of both the chemical and biophysical properties as a function of the 
biological response. Thanks to these studies we developed a versatile 
biomaterials platform with tailorable physico-chemical and biological 
properties suitable both for in vitro culture and in vivo tissue engineering 
applications. 
In particular, this biomaterials library was further investigated to design a 
novel photopolymerizable matrix for three-dimensional cell encapsulation 
and microfluidic applications needed for later stages of this work. To this 
aim, RGD-mimic diacryl amide-terminated PAA oligomers were conjugated 
with Jeffamine®. The novel triblock copolymer obtained was able to 
Chapter 6 
 
Page 120 !  
promote high surface cell adhesion and proliferation and sustained cell 
viability in 3D. Further, high pattern fidelity and resolution were 
demonstrated in the fabrication of perfusable endothelialized microfluidic 
channels. These studies support the use of PAA-based hydrogels as 
tunable and inexpensive biomaterials for the creation of complex cell-
laden microengineered constructs. 
In order to match the requirements of hierarchical porosity and 
roughness, mimicking the complexity of the in vivo milieu, we developed 
macroporous PAA hydrogel foams. PAA foams were able to promote cell 
adhesion and enhance three-dimensional endothelial cell growth in vitro. 
Biocompatibility and the capacity to promote cell migration within OPAA 
foams were demonstrated through subcutaneous implant in murine 
model. In vivo results indicate that PAA foams have the potential to 
induce vascularization thanks to their RGD-mimicking sites, which are 
able to promote endothelial cell adhesion and proliferation. The extensive 
investigation of both the physico-chemical behavior and biological 
response demonstrated that PAA foams are able to provide appropriate 
scaffolding to support and guide soft tissue growth.  
Despite significant successes have been achieved in the field of tissue 
engineering, insufficient mass transport is still limiting the size of the 
engineered tissues to smaller than clinically relevant dimensions. Novel 
solutions are required to reduce the gap between the nutrient diffused 
region in the scaffold and the desired construct size. To this aim, we 
developed an innovative fabrication approach to engineer porous and cell-
laden hydrogel scaffolds with a perfusable microfluidic network. This 
approach was demonstrated to be suitable for the creation of densely 
populated vital tissue constructs with perfusable branching 
endothelialized channels. In vitro perfusion was efficiently performed 
using a customized bioreactor, specifically developed for the perfusion of 
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soft hydrogel scaffolds. One key advantage of this technology is that the 
perfusable scaffold is formed in a one step process simply by filling the 
empty volume around the sacrificial template, crosslinking the matrix and 
then dissolving the template. This rapid method prevents the formation of 
a necrotic core in thick cellular construct, indicating that this technology 
could provide a solution to scale current engineered tissue to clinically 
relevant dimensions. 
Overall, the reported results have important implications in soft tissue 
engineering, especially in the design of vascularizable scaffolds for 
adipose tissue regeneration. Current approaches in this field rely on both 
controlling and recruiting of a vascular network. These constraints could 
be satisfied leveraging our technology platform in order to design scaffold 
composites able to control and guide angiogenesis both in vitro and in 
vivo. To achieve this goal and optimize the techniques described in this 
thesis, different challenges still remain. One of the main challenges 
resides in the optimization of the microstructural parameters of the 
scaffold to fine-tune the fluids and biomolecules dynamics within the 
scaffold. This optimization, so far hampered by design limitations, would 
allow: i) to mimic the natural tissue growth in vitro, providing suitable 
conditions for vascularization; ii) to enable in vivo angiogenesis, 
enhancing vessels ingrowth within the scaffold and favoring the 
anastomosis with the host vasculature.  
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1. Introduction 
Globally defined as the application of nanotechnology to the clinical arena, 
nanomedicine has its roots in the same basic concepts and principles of 
nanotechnology, i.e. materials with the nano-scale features present 
unique characteristics, otherwise absent at a macroscopic level [1]. Just 
as nanotechnology benefits from mathematics and engineering, 
nanomedicine too has a multidisciplinary nature involving notions and 
techniques borrowed from biology, chemistry and physics [2]. As a result 
of this successful marriage, nanostructure materials display emerging 
functions that have exceptional benefits when applied to medical devices.  
The success of nanotechnology in the healthcare sector is driven by the 
possibility to work at the same scale of several biological processes, 
cellular mechanisms and organic molecules; for this reason, medicine 
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has looked at nanotechnology as the ideal solution for the detection and 
treatment of many diseases. One of the many applications of 
nanotechnology to the medical sector is in the field of drug delivery. The 
advent of protocols and methods for the synthesis, functionalization, and 
use of nanoparticles and nano-carriers has flooded the scientific and 
clinic community with new therapeutic approaches from molecular 
targeting to radiofrequency ablation, from personalized therapies to 
minimally invasive techniques.  
While most members of the investment community are able to grasp the 
meaning of nanotechnology and can expertly launch and manage a viable 
product into the market, they are limited in their conceptual 
understanding of this scientific discipline and the intricate inner workings 
behind the product’s functionality.  [3] On the contrary, those involved in 
the scientific research recognize that nanomedicine is an expansion of 
nanotechnology, but have very little understanding of the business 
expertise required to develop their technologies into a commercial 
product. [3] Cooperation is therefore needed between the two factions in 
order to lead nanomedicine-based inventions to a successful market 
position. 
 
2. Nanomedicine Market 
With 76% [4] of the publications and 59% [4] of the patents, drug delivery 
is the market segment that dominates the nanomedicine sector. In vitro 
diagnostics represent the second leading field, contributing with 11% [4] 
of the publications and 14% [4] of the patent filings. According to the 
European Commission [4] in a global vision, clustering the publications in 
the three geographical areas USA, Europe and Asia (Japan, China, South 
Korea, Taiwan, Singapore and India) Europe is leading with 36% [4] of the 
worldwide publications, followed by the USA with 32% [4] and Asia with 
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18%. [4] Considering all patent applications in the different fields of 
nanomedicine, USA hold a share of 53%, [4] Europe has 25% [4], and 
Asia 12%. [4] Biopharmaceutical and medical devices companies are well 
aware of the potential applications of nanotechnology to the healthcare 
sector, as demonstrated by the increasingly growing partnerships 
between these enterprises and nanomedicine start-ups.  
According to a research report from Business Communications Company 
(BCC) Research, despite the catastrophic consequences of the 2008-09 
crisis on capital markets, the global nanomedicine sector, which was 
worth $53 [5] billion in 2009, is projected to grow at a compound annual 
growth rate (CAGR) of 13.5%, surpassing $100 billion in 2014 (See 
Figure 1a) [5]. One of the largest segments of this market is represented 
by anticancer products. Valued about $20 billion [5] in 2009, it is 
expected to reach $33 billion [5] in 2014, growing at a CAGR of 11% [5] 
(see Figure 1b.). 
 
Figure 1a. This graph shows the global nanomedicine market size, measured in terms of 
revenues, such as sales revenues, grants revenues and milestones. From 2006 to date, 
a steady growth has occurred, which is expected to continue through 2014, at a CAGR of 
13.5% [5]. 
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Figure 1b. The graph illustrates the market size for the anticancer applications segment. 
Except for a slight decrease in 2008, the market has and it is predicted to expand, by a 
factor of steady growth [5].  
 
3. Financing of Nanomedicine 
3.1. Common issues in the investments on innovation 
In The primary output of innovation is obtaining the know-how, which the 
inventor initially possesses. Unfortunately, the confidentiality of this 
knowledge can be breached and its use by one company cannot preclude 
the use of the same by another one.  Therefore, investors approaching 
novel projects are aware of the fact that they will not be able to easily 
appropriate the total returns of the investment undertaken. As a 
consequence, there is a lack of attractiveness in financing innovative 
projects. In fact, from the perspective of economic theory, it is complex to 
find funding for innovative ideas in a competitive market place. [6] Even 
in large firms, there is evidence of shortages in resources to spend on 
the innovative projects that the managers would like to undertake. [6] 
There are a number of reasons for this phenomenon: low expected 
returns due to an incapacity to capture the profits from an invention, the 
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exaggerated optimism in undertaking an investment on breakthrough 
projects and most notably the uncertainty and risk associated with these 
projects. Technology-based companies can also consider imitating the 
inventions developed by competitors. However, Mansfield et al [7], using 
survey evidence, found that imitating is not costless, and could result in 
expenses equal to 50% [7] to 75% [7] of the cost of the original 
invention, not eliminating the underinvestment problem. Policymakers are 
trying to change the funding situation, by facilitating the invention 
process, rationalizing the interventions through government 
encouragement of innovative activities, sustaining the intellectual 
property system, allowing Research & Development tax incentives, and 
supporting research collaborations. Nonetheless, the path that leads the 
nano-scale outcome from the laboratory to the marketplace is long and 
expensive, putting the inventor in a position of disadvantage. 
 
3.2. Asymmetric information, credibility and commitment 
The financing and management of innovative products in nanomedicine – 
like many young and innovative multi-sectoral fields – happens in a 
context of both financial and product markets failures. These make the 
financing and management of innovation a particularly complex process, 
which is also reflected in the corporate governance structure of innovative 
firms.  
Asymmetric information, transaction costs, intangible goods, credibility 
and commitment issues, jointly with high and unique risks, make it 
impossible for traditional financial institutions to be part of the picture, 
paving the way for angel investors, seed and venture capital investors, or 
other forms of non-traditional financial institutions. 
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The asymmetric information issue is partly due to the different 
information set in the hands of the innovator as opposed to that of the 
possible provider of funds (Admati and Pfleiderer 1994) [8], which gives 
rise to a “two-sided incentive problem” (Hellmann 1998) [9]: the best 
incentive to reconcile the conflicting behavior of entrepreneur 
(unobservable efforts) and venture capitalist (monitoring costs) is multi-
stage financing. In an alternative approach, staged financing solves the 
lack of credibility and of an adequate commitment technology on the part 
of the entrepreneur.  
The credibility and commitment issues arise because the entrepreneur 
possesses a “unique human capital” (Neher 1994) [10]: once the 
Venture Capital has provided financing, the entrepreneur can decide to 
withdraw and, therefore, hold the VC hostage of his/her decisions. In 
such conditions, the VC would not provide financing, as the entrepreneur 
cannot make a credible commitment not to withdraw. The solution in this 
case is the “staged capital commitment” similar to Hellmann (1998) [9] 
with a different rationale: the unique human capital of the entrepreneurs 
must be blended with the firms in various sequential stages. This leads 
to a progressive increase in the expected value of the firm (in terms of a 
future Initial Public Offering), so that the initial investments become the 
collateral (the firm itself) for the VC, providing the right incentive to 
continued financing.  
The two approaches also require both the entrepreneur and the VC to 
participate in the ownership of the firm (as financing happens with 
shares), and therefore an evolving strategic and managerial relationship 
between the two parties in an evolutionary view of the firm (Arnone and 
Giacometti 1999) [11]. Often the VC possesses very good managerial 
skills, due to its experience in dozens of start-ups, while the innovating 
entrepreneur has little or none. Against this backdrop, the staged 
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financing with shares (i.e., joint ownership) also helps addressing the key 
issue of management decisions: at the beginning of the ‘relationship’, 
the entrepreneur has the most detailed technical knowledge and almost 
complete managerial powers to set up all the technical work that needs 
to be embodied into the firm. As this knowledge is transferred to the firm 
other managerial aspects take priority (e.g. competition, finance and 
governance) where the VC has better skills. By increasing VC ownership 
in stages, management powers can be transferred to VC-appointed 
managers, with specific skill in running an evolving start-up firm and take 
it adequately to the market, usually with an IPO. 
Due to significant concern and disapproval for fundraising in support of 
innovation, fledgling nanomedicine companies, do not have an endless 
number of financial options. Therefore, in order to establish start up 
companies, co-funders generally commit their own money and expertise 
into it. This is one aspect that represents the internal capital of the start-
up, as opposed to the external one, which has to be collected from other 
sources. At this stage start-up companies turn towards government and 
foundations’ grants (i.e. the National Institutes of Health, and the 
National Science Foundation programs), in order to finance the research 
and development of their innovative products. These funds are also 
intended to protect the intellectual property of these novel discoveries 
and to attract professional investors.  
In order to expand and sustain their business, nanomedicine start-ups 
usually begins by turning to angel investors - private financiers who 
provide seed fundings - then to Venture Capitalists (VCs). The interaction 
and support of these professional investors is essential to assess 
whether a market entry is possible and to decide which market share 
managers can realistically achieve at different time horizons. In fact VCs 
enter at a specific moment of the life of the company when it is still in an 
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early stage, but has already strongly proved its value and perspective. 
According to Paul A. Gompers and Yuhai Xuan, the general role of VCs is 
to alleviate asymmetric information between private venture capital-
backed targets and the public acquirers, building a bridge between the 
two parts [12]. These funds plan investment decisions in order to 
decrease possible agency costs that afflict young entrepreneurial 
companies. Venture capitalists usually add value to companies in which 
they invest beyond pure financing, providing managerial expertise, 
industrial experience, contacts and – not least – momentum. [12] There 
is strong evidence of VCs involvement in the management of the financed 
nanotechnology companies as they often have higher costs and longer 
development times compared to an equivalent information technology 
business. Furthermore, Backer and Gompers [13], asserted that venture 
capital-backed firms have better boards of directors compared to those 
not financed by VCs. This evidence confirms the crucial role played by 
VCs in the economic success of nanomedicine-based products.   
Corporate finance literature has devoted a meaningful stream of research 
to the relevance of board composition as a useful tool against different 
typologies of asymmetric information and agency costs. Literature has 
clearly underlined the existence of a connection between firms’ 
performances and board composition. However, notwithstanding these 
important results, there is not a universally accepted evidence about the 
optimal board composition that allows the minimization of the above 
mentioned agency costs. In the VC literature evidence, a board composed 
by internal, external and instrumental (Baysinger and Butler 1985) [14] 
should achieve the result of the minimization of agency costs that is a 
propaedeutic step for a feasible way out for VC investors.   
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3.3. Landscape 
In 2007 investment in nanotechnology by VCs was US $702 million [15], 
involving 61 deals. 27% [15] went to healthcare and life science, 31% 
[15] to energy and environment, and 42% [15] to electronics & IT. Two 
years later, nanotechnology market captured US $792 million from VCs. 
[15] Of these, the largest share (51%) [15] went to healthcare and life 
sciences, followed by energy and environment, and electronics & IT, with 
23% and 17%, respectively. [15] Doubling the funds invested in the 
healthcare segment in just two years, the VC industry has demonstrated 
a clear interest in investment opportunities in the nanomedicine field 
(See Figure 2.a and 2.b). 
!  
Figure 2. VC funding of nanotechnology in 2007 (a) and 2009 (b). The pie charts 
demonstrate the attractiveness of nanomedicine market for venture capital investors. 
Captivated by the great potential of future development, in only two years VCs have 
shifted their focus on the ‘science of the tiny things’, nearly doubling investments in this 
sector.  
 
Although venture capital investors want to continue to be involved in the 
science & technology of the small scale, they are extremely cautious 
about large investments in nanotechnology and nanomedicine, as 
positive returns on investments are expected only in the long term, 
especially for nanomedicine. [3] VCs and private investors are still burned 
by the sub-prime crisis of 2008 [16], which took a serious toll on their 
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assets, causing catastrophic losses to the whole financial community and 
restricted access to funds. However, the decline of fundraising might also 
be a result of ordinary funding cycles, with several VCs having already 
raised enough resources for the short term. [17] Experts see the Wall 
Street’s crisis of 2008, as a possible regime-change [16], rather than a 
temporary market malfunctioning. After four decades of fairly 
straightforward access to relatively inexpensive capital, capital markets 
are currently undergoing major changes. [16] According to the National 
Science Foundation, innovation is an essential source of competitiveness 
for economy [18] and represents an excellent opportunity to sustain the 
economic recovery after the 2008 crisis. As usually happen after a crisis, 
investors become risk adverse, adopting more rigid risk-cover policies, 
but there is evidence that the nano-business seems to be too attractive 
not invest in. 
 
4. Business Strategies 
The main business area characterizing a nanomedicine company, as well 
as pharmaceutical and biotechnology industries, is the research and 
development (R&D). Choosing the R&D strategy, managers evaluate two 
possible options. The first is based on the idea to perform the entire 
process inside the company, composing a highly experienced team of 
scientists. The second option is based on universities or research 
institutes and is founded on the reliance on leading academic 
laboratories created over time by “scientific stars”. This second 
possibility will certainly reduce company costs as these academics 
frequently co-found the companies based on their discoveries and 
become part of the scientific boards. We have gathered strong evidence 
of this second option for the R&D strategy in the companies we analyzed. 
The commercialization of the research-based product might represent 
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another business area of the nanomedicine company. However, the 
typical option considered and adopted by managers is to license out the 
manufacturing and commercialization of the nanomedicine-based product 
to larger companies. If this is the case, the business model pursued will 
not include commercialization, and the company will be technology and 
research based.  
The commercialization of the nanomedicine products/technologies is 
currently driven by start-ups and Small-medium enterprises (SMEs) [4] 
and it is performed through three types of business models: 
1. The development of a nanotechnology platform that can be used to 
add value to second-party products: this business model seems to be 
particularly attractive for drug delivery companies, which typically license 
their particular technologies out to pharmaceutical industries. Otherwise 
the drug delivery system is tailored and applied to a specific drug 
complying the particular instructions of the larger company. [4] 
2. The development and manufacturing of high-value materials for the 
medical device and pharmaceutical industry: several start-ups and SMEs 
merely provide nanomaterials for the manufacture of medical devices or 
nanotechnology-enhanced drugs. [4] 
3. The development of nanotechnology improved medical devices or 
pharmaceuticals: companies adopting this business model intend to 
develop a proprietary product pipeline as well as trying to bring to the 
market place new or standard drugs delivered with a drug delivery system 
or else to develop, for example, a new diagnostic platform based on 
nanotechnologies. [4] 
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5. Regulatory Risk 
The U.S. Food and Drug Administration’s long approval procedure and 
regulations make nanomedicine products different from those of other 
industries using nanotechnologies with no limitations due to regulatory 
bodies. As a consequence, the expenditure to bring a nanomedical 
product to the marketplace is so huge that pharmaceutical and 
biotechnology industries have no alternative but focus on the 
blockbusters that can please the stockholders. [3] Nanoparticles are not 
inevitably hazardous, but they have unique properties that question their 
safety. It is reasonable to presume that nanomaterials are ‘new for safety 
evaluations purposes’ [3], and therefore they merit careful regulatory 
oversight by FDA both before and after entering the marketplace. In this 
arena, federal agencies like the FDA and the U.S. Patent and Trade Mark 
Office (PTO), impose a sort of order, for the protection of the population 
safety, while encouraging the development of these products. 
The advent of nanomedicine, besides causing changes in the 
biopharmaceutical industries’ business model and value chain, brought 
two crucial regulatory issues: difficulties in product classification and a 
lack of scientific expertise on the part of the FDA. [19]  
On the basis of the product’s principal method of action the FDA 
classifies nano-products as drugs, devices, or combination thereof. For 
regulatory purposes the FDA applies the same requirements to each part 
of the combination product and verifies whether the manufacturer gave 
the correct definition to the product. The definition becomes extremely 
ambiguous novel for nano-based drug delivery devices as they can be 
considered either devices (carriers) or drugs (effectors). [20] [21] The 
FDA will face exceptional challenges in efficiently regulating such 
products. In order to successfully do so, a strong scientific knowledge of 
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the field is essential together with a better understanding of the potential 
risk associated to the exposure of patients to nanomedical products. [21]  
 
6. Best practices in the Clinic 
Bringing new products to the market has always represented a great 
challenge, especially when it comes to highly innovative products with 
high risk/high return. Despite the numerous entry barriers of the 
nanomedicine market, there are some noteworthy examples of nano-
based, FDA-approved products that successfully reached the market, 
impacting medicine and anticipating a change in the healthcare arena.  
Within the anticancer products segment, DoxilTM and AbraxaneTM are 
two main examples of success in the clinic. Sequus Pharmaceutical was 
the first company to sell Doxil, the liposomal formulation of Doxorubicin, 
a powerful but toxic chemotherapic, initially approved for treatment of 
Kaposi’s sarcoma in the USA in 1995. [22] Sequus was then acquired in 
1998 by ALZA Pharmaceutical for US $580 millions [23], which 
subsequently merged with Johnson and Johnson in 2001 in a US $12.3 
billions deal. [23] The other approved nano therapeutic agent, Abraxane, 
instead, was originally sold by Abraxis Biosciences, which was acquired in 
June 2010 by Celgene Corporation for US $2.9 billions. [24] Granted by 
the orphan drug designation in January 2005 by the FDA, this product 
consists of albumin nanoparticles containing paclitaxel, and is indicated 
for the treatment of breast cancer [22]. Conventional chemotherapies 
consist of injections of cytotoxic drug intravenously, which indiscriminately 
kill both healthy and tumor cells. The clinic success of DoxilTM and 
AbraxaneTM was driven by their ability to concentrate preferentially in 
tumors, because of the gaps (otherwise called endothelial fenestrations) 
characterizing the blood vessels that supply the cancerous mass. 
Nanoparticles of the right size can penetrate these “gates” and passively 
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diffuse into the tumors. [25] Thanks to this generation of 
chemotherapies, patients are now benefiting from new treatment 
strategies for delivering drugs through nanotechnology carriers with lower 
systemic toxicity and improved therapeutic efficacy. [22]   
The economic success of these nanomedical products is driven by an 
urgent demand of new anticancer therapies able to better fight this highly 
aggressive and increasingly frequent disease. In fact, the FDA 
problematic regulatory process, the unsteady funding situation, and the 
expensive and lengthy R&D process did not thwart the development and 
success of DoxilTM and AbraxaneTM.  
Despite being the most profitable, anticancer delivery systems are not 
the only clinically approved nanomedical products. In fact, advances in 
nanomedicine are bringing breakthroughs in other problematic areas of 
medicine. Following are some examples of successful nano-enabled 
biomedical products currently on the market. 
The first successful application of nanoparticles in the clinic was 
OmniscanTM, the leading injectable paramagnetic resonance product of 
Amersham. This contrast agent was approved for Magnetic Resonance 
Imaging (MRI), launched in 1993, and utilized ever since both in 
neurology, to detect strokes and brain tumors, as well as in cardiology. 
This contrast agent - originally developed by Salutar – has prolonged half-
life in patients with renal insufficiency. After the conduction of pre-clinical 
testing, Salutar was acquired by Nycomed, which in turn purchased 
Amersham International, in 1997. Currently, Amersham and its rights on 
Omniscan are propriety of General Electric Healthcare. The deal was 
closed in 2003 for US $9,5 Billions on an all-stock transaction. According 
to G.-P.Yan et al. (2007) [26] and as confirmed by Spiess (2011) [27], 
there are 12 different MRI contrast agents currently on the market. [28] 
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MagnevistTM was marketed by Bayer Schering Pharma as their first 
intravenous contrast agent employed in the clinic. In 2004, the company 
demonstrated that the product safely and effectively eases the 
visualization of cranial and vertebral anatomy among cancers and wounds 
and since then it is diffused worldwide with that specification of use. 
[29]. Another competitor is OptiMARKTM, a gadolinium-based contrast 
agent (the only FDA-approved for administration by power injection) for 
MRI of brain, liver and spine. [30] Produced by Mallinckrodt, it allows the 
visualization of lesions with atypical vascularity. Finally, MultihanceTM is 
the first extracellular fluid contrast agent to posses interaction with 
plasma proteins. Bracco Group produces this contrast agent – an Italian 
company specialized in diagnostic imaging, drugs and devices – and is 
utilized in diagnostic MRI of the liver and Central Nervous System (CNS). 
It was launched in Europe in 1998, and received the FDA approval for 
market the product in the United States in 2004. [31] 
Returning to the segment of the pharmaceutical applications of 
nanomedicine, it is important to remember the two FDA-approved 
nanoparticles-based drugs applied for the treatment of severe fungal 
infections: AmBisomeTM (liposome for injection), sold by Gilead Sciences 
and Fujisawa Healthcare and AbelcetTM,(lipid complex), marketed by Elan 
Corporation. Liposomal formulation of amphotericin B (AmBisomeTM, in its 
trade name) was originally one of the income-making drugs of NeXstar 
Pharmaceuticals. The company, along with its products portfolio, was 
then acquired by Gilead in March 1999. For what concern AbelcetTM (the 
conventional amphotericin B), its North America rights were acquired by 
Enzon Pharmaceuticals in 2002, in an operational and profitable deal of 
$360 million (including facilities and operating assets related to the 
development, production and sale of the drug). The drug was employed in 
the treatment of patients with aggressive fungal infection associated to 
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cancer, organs transplantation and other postsurgical complications. [32] 
We wanted to emphasize theses two specific products also because they 
have been subject of a “pharmacoeconomic study”. As a result of the 
analysis, that involved the two drugs in the empirical treatment of 
persistently febrile neutropenic patients with presumed fungal infection, 
AmBisomeTM was found to be more cost-effective compared to AbelcetTM. 
[33] 
RenaZorbTM, sold by Spectrum Pharmaceuticals, represents another case 
of a nano-enabled product, which fruitfully reached the marketplace for 
the treatment of Hyperphosphatemia in End Stage Renal Disease (ESRD) 
and potentially Chronic Kidney Disease (CKD). RenaZorbTM is a 
lanthanum-based phosphate-binding agent currently in clinical trial, 
utilizing Spectrum’s proprietary nanoparticle technology. [34] The 
economic and clinical success of this nanoparticle is mainly driven by the 
clinical scenario. According to the National Kidney Foundation., only in the 
U.S are estimated to be more than 20 million people with CKD with 
numbers expected to double over the next decade. These patients live on 
kidney dialysis, and are potential candidates for phosphate binder 
therapy. [35] 
In the light of all this overview of the best practices in the clinic, 
anticancer remains the biggest share of the nanomedicine market, 
besides for number of publications and patents, also for number of 
commercialized products. Increasing acceptance with the general public 
of the employment of nanotechnologies in the clinic, along with popular 
widespread sensitivity for the aggressiveness of cancer can be 
considered strong drivers for the commercial success of this segment. 
Furthermore, the first tangible considerable returns due to commercial 
triumphs, represent an undoubted source of attraction for investors. On 
their part, financiers must realize the importance of providing the 
Appendix 
 
Page 139 !
substantive funds, necessary to gain the solid results and successful 
drugs as well as devices and therapies the market requires. The effective 
investments on DoxilTM, AbraxaneTM, as well as on the other mentioned 
successful products are prime examples of this practice. 
 
7. Conclusions and Future Promises 
Despite the issues nanomedicine still has to face, investments in this 
market are predicted to increase. New applications of nanomedicine have 
been demonstrated and the resulting expansion of the potential market 
makes the risk more appealing. Ferocious financial collapse elevated 
sunk costs of the essential R&D process, tricky access to funds, 
uncertainty of expected returns, and the extremely meticulous and lengthy 
FDA regulatory process have not deterred the investors’ community. On 
the other hand, the promises of great future potential developments in 
the different market segments and high returns connected to the high 
risk of the innovation investments make this market still considerably 
attractive. Compared to the 2007 benchmark, VCs in 2009 decided to 
double their investments in this sector, at the expenses of the 
information technology market. The fact that nanomedicine dominates the 
VC fundings in the healthcare market is surely a good predictor of the 
bright future landscape of expansion of this promising area of research. 
Moreover, good returns could even be the result of more accurate 
assessments of the investments’ risks. A pharmacoeconomic analysis 
would allow the efficient allocation of the monetary resources and the 
maximization of the highest health return at the lowest costs. A cost-
effectiveness analysis (CEA) is structured with a comparison of the costs 
and effects of two or more treatments, which are under examination. 
Whereas in the very early stage of the drug development cycle the high 
failure rate for novel drug molecules is largely due to a not adequate 
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therapeutic index, in the clinical development phase, this rate originates 
from economic reasons. Therefore, the development of unsuccessful 
drugs has to be abandoned very fast, in order so save resources for more 
promising compounds. This saving is obtained through an accurate 
economic evaluation performed in the early stages of the development 
process. The benchmark is represented by life-years saved by the 
investigated nanotherapeutic; if a nano-enabled therapy does not save 
sufficient life-years to break-even, it should not be developed further. [36] 
The major limit to the success of this kind of analysis is given by the 
scarcity of clinical data concerning nanomedicine. The best solution to 
this issue is collaboration. According to Bosetti and Vereeck, [36] 
economists and investors specialized in health market should work 
closely with healthcare providers, researchers, patients associations, 
doctors and technologists of all kinds, to creating a shared platform able 
to facilitate communication between parties with the ultimate aim to 
reduce the high risks associated to investments in nanomedicine. As a 
result, also patients will benefit from these investments, in terms of 
innovative techniques, therapies, devices and drugs designed to extend 
and improve their lives.  
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In this work, customizable biocompatible hydrogels were combined with 
innovative fabrication approaches to engineer scaffolds with controlled 
chemical, mechanical and biological features and a hierarchical three-
dimensional architecture. The abilities of these scaffolds to supply 
nutrient perfusion and mass transport, and to promote in vitro 
vascularization in large constructs are evaluated and discussed in detail.  
An introduction to the thesis and the relevant scientific background 
regarding this study is given in the Chapter 1.  
In Chapter 2 the design of novel biocompatible poly(amidoamine) (PAA) 
based hydrogels with wide and controlled degradation rate and improved 
mechanical and biological properties for biomedical applications is 
presented. Poly(amidoamine) (PAA) hydrogels containing the 2,2-
bisacrylamidoacetic acid-4-amminobutyl guanidine monomeric unit have a 
known ability to enhance cellular adhesion by interacting with the RGD-
binding αVβ3 integrin, expressed by a wide number of cell types. The 
scientific interest on this class of materials has been traditionally 
hampered by their poor mechanical properties and restricted range of 
degradation rate. Here, we present the design of novel biocompatible, 
General Summary 
 
Page 144 !  
RGD-mimic PAA-based hydrogels with wide and tunable degradation rate 
as well as improved mechanical and biological properties for biomedical 
applications. This is achieved by radical polymerization of acrylamide-
terminated PAA oligomers (OPAA) both in presence and absence of 2- 
hydroxyethylmethacrylate (HEMA). The degradation rate is precisely 
tunable by adjusting the PAA oligomer molecular weight and the acrylic 
comonomer concentration in the starting reaction mixture. Cell adhesion 
and proliferation tests on Madin-Darby Canine Kidney (MDCK) epithelial 
cells show that PAA-based hydrogels have the capacity to promote cell 
adhesion up to 200% compared to the control. Mechanical tests show 
higher compressive strength of hydrogels containing acrylic chain 
compared to traditional PAA hydrogels. The results presented in this 
study indicate that these PAAs hydrogels are excellent biomaterials for 
the fabrication of tissue engineering scaffolds. 
PAA hydrogels were further investigated in Chapter 3 to design a novel 
photopolymerizable matrix for three-dimensional cell encapsulation and 
microfluidic applications, needed for later stages of this work. To this aim 
a novel triblock copolymer (OAPAO) is synthesized by conjugating 
Jeffamine® and RGD-mimic diacryl amide-terminated poly(amidoamine) 
oligomers (OPAA), described in Chapter 2, through a simple polyaddition 
step. The hydration, mechanical and degradation properties of OAPAO 
were demonstrated to be tunable through modification of 
macromonomers’ molecular weight and concentration. OAPAO bulk 
hydrogels were tested with NIH 3T3 murine fibroblast and human 
umbilical vein endothelial cells (HUVECs), showing the ability to strongly 
promote cell adhesion and proliferation. OAPAO hydrogel was used for 
encapsulation of murine fibroblasts to form cell-laden hydrogels. 
Encapsulated cells showed viability and proliferation similar to the one 
embedded in agarose gels.  High pattern fidelity and resolution of OAPAO 
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were demonstrated in the fabrication of perfusable microfluidic channels. 
Overall, these studies support the use of OAPAO hydrogels as tunable 
and inexpensive biomaterials for the creation of complex cell-laden 
microengineered constructs. 
In order to recreate the complex microarchitecture of natural extracellular 
matrix, open cell macro porous foams of PAA hydrogels were fabricated, 
as described in Chapter 4. RGD-mimic OPAA oligomers, described in 
Chapter 2 and 3, were cross linked via free radical polymerization, using 
ammonium persulfate as initiator, and ammonium bicarbonate as 
foaming agent, obtaining solid scaffolds with optimal hierarchical porosity 
and roughness. The capacity of PAA foams to promote cell adhesion and 
proliferation in 3D-cell culture has been evaluated in vitro for HUVECs. 
Biocompatibility and the capacity to promote cell migration inside OPAA 
foams were demonstrated through subcutaneous implant in murine 
model. The extensive screening of the biological, chemical and 
mechanical properties demonstrated that OPAA foams are able to support 
and enhance three-dimensional cell growth and can be considered an 
optimal scaffold for soft tissue engineering. 
In Chapter 5 the development of innovative fabrication approaches to 
engineer scaffolds with a perfusable microfluidic network is presented. 
Branched microfluidic networks were embedded within hydrogel matrices 
through an innovative method based on sacrificial templates. Results 
demonstrated that perfused microfluidic networks are able to sustain the 
cell viability of murine fibroblasts in the core of hydrogel cell-laden 
constructs. These microfluidic networks, when seeded with endothelial 
cells and perfused in customized perfusion bioreactor are able to form 
one-layer tubular endothelium hierarchically branched as a vascular 
network. This innovative approach was demonstrated to be suitable for 
the creation of densely populated vital tissue constructs with perfusable 
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branching vascular channels. Compared to other methods, it represents a 
progress in manufacturability and scalability, being compatible with a 
wide range of synthetic and natural biomaterials, crosslinking strategies 
and polymerization reaction. 
In Chapter 6, there is a general review of the results obtained in this 
work. In this chapter we conclude that combination of customizable PAA 
hydrogels with innovative fabrication approaches, to control the 3D 
scaffold architecture and mass transport dynamics, create a 
technological platform able to give a viable solution to the vascularization 
problem in tissue engineering, as originally aimed in this thesis work. We 
forecast that this combined strategy will allows new scenarios towards 
the engineering of thick and complex soft tissues. 
APPENDIX A explores issues involved in technology transfer of 
nanomedicine products. A detailed analysis of market, competitors and 
investors in the sector has been performed, further supported by one-to-
one interviews to both American and European market experts. This 
overview aims to help scientists, startup mangers and investors to 
understand the key dynamics and successful cases in the transfer of 
nanotechnology in medicine.  
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